Angiogenesis inhibitor

专利摘要:
An object of the present invention is to discover a new pharmacological action of a urea compound having a structure represented by the general formula [1]. The urea compound having a structure represented by the formula [1] has an excellent angiogenesis inhibitory effect. [Wherein A is-(NR 4 )-,-(CR 5 R 6 )-or -O-, B is an alkylene or alkenylene group, R 1 , R 2 , R 4 , R 5 and R 6 Represents a hydrogen atom, an alkyl group, an alkenyl group, an adamantylalkyl group, R 3 represents an aryl group or an unsaturated heterocycle, and X represents an oxygen atom or a sulfur atom.]
公开号:KR20040058349A
申请号:KR10-2004-7008167
申请日:2002-11-29
公开日:2004-07-03
发明作者:마츠오카히데히토；니시무라카즈오；세이케히사유키；아오노히로유키；무라이마사아키
申请人:산텐 세이야꾸 가부시키가이샤；
IPC主号:

专利说明:

Angiogenesis Inhibitor {ANGIOGENESIS INHIBITOR}
[2] Vascular homeostasis is maintained by various functions of endothelial cells. Vascular endothelial cells, 1) mediate the transport of necessary components, such as nutrients in the blood, to prevent unnecessary passage of large amounts of components, 2) smoothly circulate without clotting blood, and 3). It has a function of preventing bleeding when the blood vessel is cut off, and 4) a regulating action of keeping the blood vessel tension constant.
[3] Angiogenesis by dissolution of basement membrane by protease produced by vascular endothelial cells, migration and proliferation of vascular endothelial cells, tube formation of vascular endothelial cells, formation of basement membrane and enveloping peripheral cells This occurs. Angiogenesis is associated with a number of diseases, in particular diabetic retinopathy, prematurity retinopathy, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascularization, solid tumors, hemangiomas, tumors It is closely related to proliferation and metastasis. Angiogenesis is thought to be caused by various growth factors, cytokines, arachidonic acid metabolites, monobutyline, and the like. Among these, proliferative factors are considered to be the most important angiogenic factors (Medical Progress, 170 , 536-539 (1994)).
[4] Thus, it is useful as a therapeutic agent for diabetic retinopathy, prematurity retinopathy, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascularism, solid tumor, hemangioma, tumor proliferation and metastasis. Searching for compounds with angiogenesis inhibitory effects is significant.
[1] The present invention relates to angiogenesis inhibitors comprising the novel urea compounds as active ingredients, and more particularly to drugs useful for ocular and cancer diseases.
[5] Disclosure of the Invention
[6] The present inventors created compounds having various chemical structures, and performed angiogenesis inhibition test using human vascular endothelial cells and angiogenesis inhibition test by high oxygen load-induced retinal angiogenesis. Novel urea compounds with structures exhibiting excellent antiangiogenic activity in any of the above in vitro and in vivo tests, and diseases involving angiogenesis, in particular diabetic retinopathy, prematurity retinopathy , Macular degeneration, angiographic glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascular disease and other diseases and solid tumors, hemangiomas, tumor proliferation, metastasis, etc. Thus, the present invention has been completed.
[7] The present invention relates to an angiogenesis inhibitor comprising as an active ingredient a compound represented by the following formula [1] or a salt thereof (hereinafter referred to as "the present compound") unless otherwise specified.
[8]
[9] [Wherein, A represents — (NR ⁴ ) —, — (CR ⁵ R ⁶ ) — or —O—; B is -O-, -S-,-(NR ⁷ )-, -CO-, -N = or
[10]
[11] The alkylene group or alkenylene group which may contain may be substituted, and this alkylene group and alkenylene group may be substituted by the hydroxyl group, the alkoxy group, the cycloalkyl group, the aryl group, the siloxy group, or the saturated or unsaturated heterocyclic ring, and it couple | bonds with A and saturated May form a heterocyclic ring;
[12] R ¹ , R ² , R ⁴ , R ⁵ and R ⁶ are the same or different and represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group, an acyl group or an amino group and the corresponding alkyl group, alke The alkyl group, alkynyl group, cycloalkyl group or cycloalkenyl group is a halogen atom, hydroxy group, amino group, cycloalkyl group, adamantyl group, aryl group, carboxyl group, alkoxycarbonyl group, aryloxycarbonyl group, aminocarbonyl group, cyano group or saturated or unsaturated heterocyclic ring May be substituted with;
[13] R ¹ and R ² , R ² and R ⁴ , R ² and R ^5, and R ² and R ⁶ may form a saturated or unsaturated heterocycle;
[14] R ³ represents an aryl group or an unsaturated heterocycle;
[15] R ⁷ represents a hydrogen atom or an alkyl group;
[16] X represents = O or = S;
[17] n represents an integer of 1 to 5;
[18] The hydrogen atom of each of the amino group, hydroxy group and aminocarbonyl group is an alkyl group, a cycloalkyl group, adamantyl group, adamantylalkyl group, aryl group, arylalkyl group, acyl group, alkoxyalkyl group, alkoxycarbonyl group, alkylaminocarbonyl group, cycloalkyloxycarbonyl group, It may be substituted with an arylalkoxycarbonyl group, an alkylsulfonyl group, an arylsulfonyl group, a halogenoalkyloxycarbonyl group, an imidazolylcarbonyl group, a pyridylcarbonyl group, a saturated or unsaturated heterocyclic ring, or an alkyl group substituted with a saturated or unsaturated heterocyclic ring. . Same below.]
[19] Because the compound has excellent angiogenesis inhibitory effect, diabetic retinopathy, prematurity retinopathy, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascularization, solid tumor, hemangioma, tumor It acts as an active ingredient in therapeutic agents for diseases involving angiogenesis such as proliferation and metastasis.
[20] Each group defined by general formula [1] is explained in full detail.
[21] Alkylene group is a methylene group, ethylene group, trimethylene group, propylene group, tetramethylene group, pentamethylene group, hexamethylene group, octamethylene group, decamethylene group, dodecamethylene group, methylene methylene group, ethylethylene group, dimethyl The linear or branched alkylene group which has 1-12 carbon atoms, such as an ethylene group, a propylethylene group, an isopropylene ethylene group, and a methyl trimethylene group, is shown.
[22] Alkenylene group has one or more double bonds such as vinylene group, propenylene group, butenylene group, pentenylene group, hexenylene group, octenylene group, butanediylidene group, methylpropenylene group, etc. A straight chain or branched alkenylene group having an atom is shown.
[23] Alkyl group is methyl group, ethyl group, propyl group, butyl group, hexyl group, octyl group, decyl group, dodecyl group, isopropyl group, isobutyl group, isopentyl group, isohexyl group, isooctyl group, t-butyl group, 3, Linear or branched alkyl groups having 1 to 12 carbon atoms such as 3-dimethylbutyl group.
[24] Alkoxy group has 1 to 12 carbon atoms such as methoxy group, ethoxy group, propoxy group, butoxy group, hexyloxy group, octyloxy group, decyloxy group, dodecyloxy group, isopropoxy group, t-butoxy group Linear or branched alkoxy group.
[25] An alkenyl group represents the linear or branched alkenyl group which has 2-12 carbon atoms, such as a vinyl group, an allyl group, 3-butenyl group, 5-hexenyl group, and isopropenyl group.
[26] An alkynyl group represents a straight or branched alkynyl group having 2 to 12 carbon atoms such as an ethynyl group, a propynyl group, a butynyl group, and the like.
[27] The cycloalkyl group represents a cycloalkyl group having 3 to 20 carbon atoms such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclodecyl group and a cyclododecyl group.
[28] A cycloalkenyl group represents the cycloalkenyl group which has 5-20 carbon atoms, such as a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group.
[29] The aryl group represents an aromatic hydrocarbon ring such as a phenyl group or a naphthyl group, and these may have one or more substituents, and examples of the substituent include an alkyl group, a cycloalkyl group, a carboxyl group, an amino group, a hydroxy group, an aminoalkyl group, a hydroxyalkyl group, a nitro group, and a sia group. A furnace group, a halogen atom, an alkyloxy group, etc. are mentioned.
[30] A siloxy group represents silicon containing organic groups, such as a trialkyl silyloxy group, a dialkyl (aryl) silyloxy group, an alkyl (diaryl) oxy group, and a triaryl silyloxy group.
[31] Halogen atoms represent fluorine, chlorine, bromine and iodine.
[32] The heterocycle represents, for example, a 5-20 membered saturated or unsaturated monocyclic heterocyclic ring or bicyclic heterocyclic ring containing 1 to 4 nitrogen atoms, oxygen atoms and sulfur atoms, and these heterocycles have one or more substituents. The substituent may be, for example, an alkyl group, a cycloalkyl group, a carboxy group, an amino group, a hydroxy group, an aminoalkyl group, a hydroxyalkyl group, a nitro group, a cyano group, a halogen atom, an alkyloxy group, an aryl group, an arylalkyl group, or a saturated or unsaturated complex. Ring etc. are mentioned. When the heterocycle has a nitrogen atom or a sulfur atom in the ring, these atoms may be oxidized to form an N-oxide, an S-oxide, or the like.
[33] Specific examples of the saturated heterocyclic ring include pyrrolidine, piperidine, homopiperidine, piperazine, nitrogen atom and morpholine having nitrogen and oxygen atoms in the ring, nitrogen atom and sulfur atom in the ring. And monocyclic heterocycles such as thiomorpholine, and these may be condensed with benzene rings and the like to form bicyclic heterocycles such as tetrahydroquinoline and tetrahydroisoquinoline.
[34] Specific examples of the unsaturated heterocyclic ring include monocyclic heterocycles such as pyrrole, pyridine, pyrazole, imidazole, pyrazine, pyridazine and pyrimidine having in nitrogen, or indole, quinoline, isoquinoline, benzimidazole, naphthyridine and the like. , Bicyclic heterocycles such as pyrrolypyridine and imidazopyridine, monocyclic heterocycles having furan atoms in the ring or bicyclic heterocyclic rings such as benzofuran, monocyclic heterocycles such as thiophene having sulfur atoms in the ring Or bicyclic heterocycles such as benzothiophene, monocyclic heterocycles such as oxazoles, isoxazoles, thiazoles and isothiazoles having a nitrogen atom and an oxygen atom or a sulfur atom in a ring or benzoxazole, benzothiazole, And bicyclic heterocycles such as thienopyridine, oxazolopyridine, thiazolopyridine and floppyridine. In addition, the above-mentioned unsaturated heterocyclic ring may be a form containing a saturated bond partially.
[35] The salts in the present invention are not particularly limited as long as they are acceptable salts as medicaments, and salts with inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid and phosphoric acid, salts with organic acids such as acetic acid, fumaric acid, maleic acid, succinic acid and tartaric acid. And salts with alkali metals or alkaline earth metals such as sodium: potassium and calcium. In addition, the quaternary ammonium salt of this compound is contained in the salts in this invention. In addition, when some geometric isomers or optical isomers exist in this compound, these isomers are also included in the scope of the present invention. The compound may be in the form of a hydrate and a solvate.
[36] As a preferable example of this invention, the following (1)-(3) is mentioned.
[37] (1) A compound or a salt thereof, wherein each group defined by the formula [1] is selected from the following groups, or a combination thereof
[38] 1) R ³ : pyridine ring.
[39] 2) at least one of R ¹ , R ² , R ⁴ , R ⁵ and R ⁶ : an adamantylalkyl group, adamantyloxyalkyl group, adamantylaminoalkyl group or adamantylaminocarbonylalkyl group.
[40] 3) at least one of R ¹ and R ² : an adamantylalkyl group, adamantyloxyalkyl group, adamantylaminoalkyl group, or adamantylaminocarbonylalkyl group.
[41] 4) at least one of R ¹ and R ² : an adamantylalkyl group.
[42] (2) Compounds or salts thereof in which each group specified in formula [1] consists of the following groups
[43] A:-(NR ⁴ )-,-(CR ⁵ R ⁶ )-or -O-,
[44] B: -O-, -S-,-(NR ⁷ )-, -CO-, -N = or
[45]
[46] Alkylene group or alkenylene group which may contain, the alkylene group may be substituted with a hydroxy group, an alkoxy group, an aryl group, a siloxy group or a saturated or unsaturated heterocyclic ring, or may be combined with A to form a saturated heterocyclic ring. Good,
[47] R ¹ : represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group or an amino group, and the alkyl group, alkenyl group, alkynyl group, cycloalkyl group or cycloalkenyl group is a halogen atom, hydroxy group, amino group, The cycloalkyl group, the aryl group, the carboxyl group, the alkoxycarbonyl group, the alkylaminocarbonyl group, the adamantyl group, the aryloxycarbonyl group, the cyano group, or the saturated or unsaturated heterocyclic ring may be substituted, and the hydrogen atoms of the above-described amino, hydroxyl and aminocarbonyl groups. Substituted with an alkyl group, a cycloalkyl group, an aryl group, an arylalkyl group, an acyl group, an alkoxycarbonyl group, a cycloalkyloxycarbonyl group, an arylalkoxycarbonyl group, a halogenoalkyloxycarbonyl group, an imidazolylcarbonyl group, an unsaturated heterocyclic ring or an unsaturated heterocyclic ring May be substituted with an alkyl group. ,
[48] R ² : an adamantylalkyl group, adamantyloxyalkyl group, adamantylaminoalkyl group or adamantylaminocarbonylalkyl group,
[49] R ³ : unsaturated heterocycle,
[50] R ⁴ : a hydrogen atom, an alkyl group, adamantylalkyl group, carboxyalkyl group, alkoxycarbonyl group, alkoxycarbonylalkyl group, amino group, alkylamino group, acylamino group or alkoxycarbonylamino group,
[51] R ⁵ and R ^{6 are the} same or different and are hydrogen atom, alkyl group, amino group or alkoxycarbonylamino group,
[52] R ^{7 is a} hydrogen atom or an alkyl group,
[53] X: = O or = S,
[54] n: integer of 1-5.
[55] It is more preferable that R <^2> is an adamantylalkyl group and R <^3> is a pyridine ring among these.
[56] Moreover, the compound or its salt which especially each group defined by General formula [1] consists of the following groups is especially preferable.
[57] A:-(NR ⁴ )-,-(CR ⁵ R ⁶ )-or -O-,
[58] B: -S- or
[59]
[60] Alkylene group or alkenylene group which may contain,
[61] R ¹ : An alkyl group or an alkenyl group, the alkyl group may be substituted with a halogen atom or an amino group, and the amino group may be substituted with an alkyl group, acyl group, arylalkyloxycarbonyl group, cycloalkyloxycarbonyl group or alkoxycarbonyl group,
[62] R ^{2 is an} adamantylalkyl group,
[63] R ³ : pyridine ring,
[64] R ⁴ : hydrogen atom,
[65] R ⁵ and R ⁶ : hydrogen atom,
[66] X: = O,
[67] n: integer of 1-5.
[68] (3) Compounds or salts thereof in which each group specified in formula [1] consists of the following groups
[69] A:-(NR ⁴ )-,-(CR ⁵ R ⁶ )-or -O-,
[70] B: -O-, -S-,-(NR ⁷ )-, -N = in the chain
[71]
[72] As an alkylene group or alkenylene group which may contain, the alkylene group may be substituted with a hydroxyl group, an alkoxy group, an aryl group, or a saturated or unsaturated heterocycle, or may be combined with A to form a saturated heterocycle,
[73] R ¹ : a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group or an amino group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group or cycloalkenyl group is a halogen atom, hydroxy group, amino group, cyclo An alkyl group, an aryl group, a carboxyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, a cyano group, or a saturated or unsaturated heterocyclic ring may be substituted, and the hydrogen atom of each amino group, hydroxy group and aminocarbonyl group of R ¹ may be an alkyl group, a cycloalkyl group. May be substituted with an alkyl group substituted with an aryl group, an arylalkyl group, an acyl group, an alkoxycarbonyl group, a cycloalkyloxycarbonyl group, an arylalkoxycarbonyl group, an unsaturated heterocyclic ring or an unsaturated heterocyclic ring,
[74] R ² : alkyl group, alkenyl group, cycloalkyl group, cycloalkylalkyl group or arylalkyl group,
[75] R ³ : pyridine ring,
[76] R ⁴ : a hydrogen atom, an alkyl group, adamantylalkyl group, carboxyalkyl group, alkoxycarbonylalkyl group, amino group, alkylamino group, acylamino group or alkoxycarbonylamino group,
[77] R ⁵ and R ^{6 are the} same or different and are a hydrogen atom or an alkyl group,
[78] R ^{7 is a} hydrogen atom or an alkyl group,
[79] X: = O or = S,
[80] n: integer of 1-5.
[81] Among these, the compound or its salt which each group prescribed | regulated by General formula [1] consists of the following groups is more preferable.
[82] A:-(NR ⁴ )-or-(CR ⁵ R ⁶ )-,
[83] B: alkylene group or alkenylene group,
[84] R ¹ : An alkyl group or an alkenyl group, wherein the alkyl group may be substituted with a halogen atom, an amino group, a cycloalkyl group, an aryl group, an imidazole group or a pyridine ring, and the amino group may be an alkyl group, an acyl group, an alkoxycarbonyl group, or a cycloalkyloxy. May be substituted with a carbonyl group or an arylalkoxycarbonyl group,
[85] R ² : alkyl group, alkenyl group or arylalkyl group,
[86] R ³ : pyridine ring,
[87] R ⁴ : hydrogen atom,
[88] R ⁵ and R ⁶ : hydrogen atom,
[89] X: = O.
[90] Moreover, among these, it is especially preferable that R <^1> is a C3 or more alkyl group and R <^2> is an alkyl group or an arylalkyl group.
[91] Moreover, the compound or its salt whose each group prescribed | regulated by General formula [1] consists of the following groups is more preferable.
[92] A:-(NR ⁴ )-or-(CR ⁵ R ⁶ )-,
[93] B: alkylene group or alkenylene group,
[94] R ¹ : an alkyl group, an alkenyl group or a cycloalkyl group wherein the alkyl group is substituted with a halogen atom, a hydroxy group, an amino group, a cycloalkyl group, an aryl group, a carboxyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, a pyridine ring or a thiophene ring The hydrogen atom of each amino group, hydroxy group and aminocarbonyl group in R ¹ may be substituted with an alkyl group, an aryl group, an arylalkyl group, an acyl group, an alkoxycarbonyl group, a cycloalkyloxycarbonyl group or an arylalkoxycarbonyl group,
[95] R ² : cycloalkyl group or cycloalkylalkyl group,
[96] R ³ ; Pyridine Ring,
[97] R ⁴ : hydrogen atom,
[98] R ⁵ and R ⁶ : hydrogen atom,
[99] X: = O.
[100] The following compounds and their salts are mentioned as the most preferable example of this compound.
[101] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea
[102]
[103] 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea
[104]
[105] 1- [2- (1-adamantyl) ethyl] -1- (2-butenyl) -3- [3- (4-pyridyl) propyl] urea
[106]
[107] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyri Dill) propyl] urea
[108]
[109] 1- [3- (1-adamantyl) propyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea
[110]
[111] (Z) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea
[112]
[113] (-)-1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea
[114]
[115] 1- [2- (1-adamantyl) ethyl] -3- [1-methyl-3- (4-pyridyl) propyl] -1-pentylurea
[116]
[117] (+)-1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [2- Methyl-3- (4-pyridyl) propyl] urea
[118]
[119] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N-pentylamide
[120]
[121] 3- (4-pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide
[122]
[123] 2- [2- (4-pyridyl) ethylthio] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide
[124]
[125] 6- (4-pyridyl) capronic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide
[126]
[127] Cis-1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridyl) cyclopropylmethyl] urea
[128]
[129] 1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea
[130]
[131] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] urea
[132]
[133] (E) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea
[134]
[135] (+)-1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea
[136]
[137] 1,1-dibutyl-3- [3- (4-pyridyl) propyl] urea
[138]
[139] 3- [2-methyl-3- (4-pyridyl) propyl] -1-pentyl-1-phenethylurea
[140]
[141] 5- (4-pyridyl) valeric acid N-pentyl-N-phenethylamide
[142]
[143] 1- (2-cyclohexylethyl) -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea
[144]
[145] Subsequently, this compound can be manufactured, for example according to the following reaction paths 1-3, It is not limited to these reaction paths, It can also manufacture by various reaction paths. In addition, the detailed synthesis | combining method is demonstrated in the Example mentioned later.
[146] Reaction route 1
[147]
[148] By reducing the amide (A) and further reacting the first amine (B) with the compound (C) having a leaving group, a second amine (D) can be obtained (in the chemical reaction formula, R ¹ and R ^2). Can be synthesized by replacing). Similarly, 2nd amine (G) can be obtained by making compound (E) which has a leaving group, and 1st amine (F) react. The first amine (B) or the second amine (D) and the first amine (F) or the second amine (G) are condensed in the presence of a condensing agent (H) [eg 1,1′-carbonyldiimidazole]. When reacted, the present compound [2] can be obtained.
[149] Reaction path 2
[150]
[151] Of a first amine (B) or a second amine (D) synthesized in Reaction Path 1 with carboxylic acid (I) as a condensing agent [for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride] This compound [3] can be obtained by reacting in the presence of the compound.
[152] Reaction pathway 3
[153]
[154] When the first amine (B) or the second amine (D) synthesized in the reaction route 1 and the alcohol (J) are reacted in the presence of a condensing agent (K) [for example, N, N'-disuccinimidyl ester of carbonate] This compound [4] can be obtained.
[155] In the above synthesis method, when the reaction substance has a thiol group, a hydroxy group or an amino group in the molecule, these groups may be protected with a suitable protecting group as necessary, and these protecting groups may be removed by a conventional method after the reaction. In addition, when a reaction substance has a carboxyl group in a molecule | numerator, a carboxyl group may be esterified as needed, and ester may be made into carboxylic acid by hydrolysis or other general methods.
[156] The compound obtained by the above-mentioned synthetic method can be used as the salts mentioned above by a conventional method.
[157] In order to investigate the usefulness of the present compound obtained by the above synthesis method, angiogenesis inhibition experiment was conducted. Although the details are shown in the pharmacological test section described later, the present compound is strongly inhibited in any of angiogenesis using in vitro human vascular endothelial cells, an angiogenesis evaluation model, and retinal angiogenesis caused by high oxygen load-induced in vivo. It was found to exhibit action. The present compounds can be used for angiogenesis inhibitors and diseases involving angiogenesis, in particular, diabetic retinopathy, prematurity retinopathy, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascularism, solid tumors. It is useful as a prophylactic agent, a therapeutic agent, and an inhibitor of hemangioma, tumor proliferation and metastasis.
[158] Administration of this compound can be performed parenterally or orally. Examples of dosage forms include eye drops, eye ointments, and subconjunctival injections, intraconjunctival depots, embedded preparations, intraconjunctival sac injections, intravenous injections, tablets, capsules, powders, granules, and transdermal absorbents. And they can be prepared using known techniques, including DDS formulations. For example, the eye drop can be prepared by appropriately blending an isotonic agent, a buffer, a pH adjuster, a solubilizer, a thickener, a stabilizer, a preservative, a non-fatting agent and the like as an additive. In addition, a stable eye drop can be obtained by suspending the drug by adding a pH adjuster, a thickener, a dispersant, and the like. It is preferable to set pH of eyedrops to 4.0-8.0, and it is preferable to set a penetration pressure ratio to 1.0 vicinity.
[159] Examples of the tonicity agent include glycerin, propylene glycol, sodium chloride, potassium chloride, sorbitol, mannitol, and the like.
[160] Examples of the buffer include phosphoric acid, phosphate, citric acid, acetic acid, ε-aminocaproic acid, tromethamol and the like.
[161] Examples of the pH regulator include hydrochloric acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, and the like.
[162] Examples of the solubilizer and the dispersant include polysorbate 80, polyoxyethylene hardened castor oil 60, macrogol 4000, refined soy lecithin, polyoxyethylene (160) polyoxypropylene (30) glycol, and the like.
[163] Examples of the thickener include cellulose polymers such as hydroxypropylmethyl cellulose and hydroxypropyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, and the like, and as stabilizing agents, for example, edetic acid and sodium edate. .
[164] As a preservative (preservative), general-purpose sorbic acid, potassium sorbate, benzalkonium chloride, benzetonium chloride, methyl paraoxybenzoate, propyl paraoxybenzoate, chlorobutanol, etc. can be used combining these preservatives.
[165] Examples of the non-solvent agent include chlorobutanol, benzyl alcohol, lidocaine, and the like.
[166] The dosage of the present compound can be appropriately selected depending on symptoms, age, dosage form, and the like, but, for example, if the eye drop is used, it is usually in a concentration of 0.001% to 10% (w / v), preferably 0.01 to 5% (w / v). It may be administered once or several times a day.
[167] Although the manufacture example of an intermediate, the manufacture example of this compound, the preparation example, and the result of a pharmacological test are shown below, these examples are for understanding this invention better, and do not limit the scope of the present invention.
[168] [A] Preparation Example of Intermediate
[169] Intermediate Preparation Example 1
[170] 2- (1-adamantyl) -N-pentylethylamine hydrochloride (Intermediate 1-1)
[171] To a ethanol (45.8 ml) solution of methanesulfonic acid 2- (1-adamantyl) ethyl ester (2.07 g, 8.01 mmol) pentylamine (2.69 ml, 23.2 mmol), potassium carbonate (2.14 g, 15.5 mmol), sodium iodide (2.30 g, 15.3 mmol) was added and it heated and refluxed for 17 hours. The reaction solution was concentrated under reduced pressure, and diluted with chloroform (100 ml). This was washed with 1N aqueous sodium hydroxide solution (100 ml) and saturated aqueous sodium chloride solution (100 ml), and the organic layer was dried over magnesium sulfate. The solvent was evaporated under reduced pressure and purified by silica gel column chromatography. To a solution of ethyl acetate (0.50 ml) in a free body (1.52 g, 6.10 mmol) of the obtained target compound was added 4N ethyl hydrogen acetate acetate solution (3.1 ml). The precipitated solid was washed with ethyl acetate and filtered off to obtain 1.33 g (60%) of the target compound.
[172] IR (KBr): 2924, 2850, 2519, 1456 cm ^-1
[173] mp: 263.0-264.5 ° C.
[174] The following compounds were obtained by the same operation as the intermediate preparation example 1. In addition, the target compound may not be isolated as a hydrochloride salt.
[175] N '-[2- (1-adamantyl) ethyl] -N- (benzyloxycarbonyl) -N-methylethylenediamine (intermediate 1-2)
[176] IR (neat): 2901, 2844, 1704 cm ^-1
[177] 2- (1-adamantyl) -N- (cyclopentylmethyl) ethylamine hydrochloride (Intermediate 1-3)
[178] IR (KBr): 2907, 2847, 1452 cm ^-1
[179] mp: 300.0-310.0 ° C
[180] N '-[2- (1-adamantyl) ethyl] -N- (t-butoxycarbonyl) -N-methylethylenediamine (intermediate 1-4)
[181] IR (neat): 3307, 2902, 2846, 1698 cm ^-1
[182] 2,2'-di (1-adamantyl) diethylamine hydrochloride (Intermediate 1-5)
[183] IR (KBr): 2900, 2845, 2735, 2453 cm ^-1
[184] mp: 325 ° C.
[185] 2- (1-adamantyl) -N-propylethylamine (intermediate 1-6)
[186] IR (neat): 3276, 2903, 2846, 1450 cm ^-1
[187] N '-[2- (1-adamantyl) ethyl] -N, N-dimethylethylenediamine dihydrochloride (intermediate 1-7)
[188] IR (KBr): 3424, 2901, 2846, 2445 cm ^-1
[189] mp: 254.5-259.0 ° C.
[190] 2- (1-adamantyl) -N-cyclopentylethylamine hydrochloride (Intermediate 1-8)
[191] IR (KBr): 2910, 2846, 2771, 2450 cm ^-1
[192] mp: 300-312 ℃
[193] 2- (1-adamantyl) -N-cyclopropylethylamine (Intermediate 1-9)
[194] IR (neat): 3272, 2901, 2845 cm ^-1
[195] 2- (1-adamantyl) -N- (2-methoxyethyl) ethylamine hydrochloride (Intermediate 1-10)
[196] IR (KBr): 2909, 2846, 2792, 1451 cm ^-1
[197] mp: 278.5-281.5 ° C.
[198] (1-adamantyl) -N- (2-propynyl) ethylamine (Intermediate 1-11)
[199] IR (neat): 2900, 2845, 1450 cm ^-1
[200] N-pentyl-2- (2-pyridyl) ethylamine (intermediate 1-12)
[201] IR (neat): 3305, 2927, 2857, 1591 cm ^-1
[202] 2- (1-adamantyl) -N-benzylethylamine hydrochloride (Intermediate 1-13)
[203] IR (KBr): 2900, 2846, 2750, 2528, 2468, 2372, 1585 cm ^-1
[204] mp: 264.0-265.0 ° C.
[205] 2- (1-adamantyl) -N-furfurylethylamine hydrochloride (Intermediate 1-14)
[206] IR (KBr): 3456, 2903, 2846, 2741, 2426 cm ^-1
[207] mp: 225.0-233.0 ° C.
[208] 2- (1-adamantyl) -N-butylethylamine (intermediate 1-15)
[209] IR (neat): 2903, 1683, 1450 cm ^-1
[210] 2-cyclohexyl-N- (2-thienyl) methylethylamine hydrochloride (Intermediate 1-16)
[211] N-pentylphenethylamine hydrochloride (Intermediate 1-17)
[212] IR (KBr): 3028, 2957, 2786, 1456 cm ^-1
[213] mp: 260.0-285.0 ° C
[214] 2-cyclohexyl-N-butylethylamine hydrochloride (Intermediate 1-18)
[215] IR (KBr): 2921, 2853, 2794, 2739, 2442, 1590, 1484,1451 cm ^-1
[216] mp: 250 ° C. or higher
[217] 2-cyclohexyl-N-pentylethylamine hydrochloride (Intermediate 1-19)
[218] IR (KBr): 2924, 2793, 1451 cm ^-1
[219] mp: 250 ° C. or higher
[220] N- (t-butoxycarbonyl) -N '-(2-cyclohexylethyl) -N-methylethylenediamine (intermediate 1-20)
[221] IR (neat): 3350, 2923, 2850, 1697, 1481, 1449 cm ^-1
[222] N '-(2-cyclohexylethyl) -N, N-dimethylethylenediamine (intermediate 1-21)
[223] IR (neat): 3310, 2921, 2850, 2815, 1448 cm ^-1
[224] N- [2- (1-adamantyl) ethyl] -3- (4-pyridyl) propylamine (intermediate 1-22)
[225] IR (neat): 3291, 2902, 2845, 1602, 1450 cm ^-1
[226] 2- (1-adamantyl) -N-isopropylethylamine hydrochloride (Intermediate 1-23)
[227] IR (KBr): 2909, 2846, 2754, 2464, 1588, 1476, 1451 cm ^-1
[228] mp: 266.0-269.5 ° C.
[229] N- (2-piperidinoethyl) pentylamine (intermediate 1-24)
[230] IR (neat): 2932, 2854, 1466 cm ^-1
[231] 2- (1-adamantyl) -N-[(2-methylthiazol-4-yl) methyl] ethylamine (intermediate 1-25)
[232] IR (neat): 2901, 2844, 1449 cm ^-1
[233] N- [2- (1-adamantyl) ethyl] cinnamilamine (Intermediate 1-26)
[234] IR (neat): 2901, 2845, 1449 cm ^-1
[235] N- [2- (1-adamantyl) ethyl] -2-methyl-2-propenylamine (intermediate 1-27)
[236] IR (neat): 2902, 2845, 1450 cm ^-1
[237] N- [2- (1-adamantyl) ethyl] -3-methyl-2-butenylamine (intermediate 1-28)
[238] IR (neat): 2903, 2846, 1450 cm ^-1
[239] N- [2- (1-adamantyl) ethyl] decylamine hydrochloride (Intermediate 1-29)
[240] IR (KBr): 2926, 2849, 2778, 2469 cm ^-1
[241] mp: 204.0-208.5 ° C.
[242] N- [2- (1-adamantyl) ethyl] hexylamine hydrochloride (Intermediate 1-30)
[243] IR (KBr): 2909, 2848, 2766, 2446 cm ^-1
[244] mp: 230.0-243.0 ° C.
[245] 2- (1-adamantyl) -N- (benzyloxy) ethylamine (intermediate 1-31)
[246] IR (neat): 2901, 2846, 1452 cm ^-1
[247] 2- (1-adamantyl) -N-[(2-thienyl) methyl] ethylamine hydrochloride (Intermediate 1-32)
[248] IR (KBr): 2908, 2846, 2757, 2426 cm ^-1
[249] mp: 257.0-260.0 ° C
[250] N- [2- (1-adamantyl) ethyl] -2-butenylamine (intermediate 1-33)
[251] IR (neat): 2901, 1450 cm ^-1
[252] N- [2- (1-adamantyl) ethyl] allylamine (Intermediate 1-34)
[253] IR (neat): 2902, 1450 cm ^-1
[254] N- [2- (1-adamantyl) ethyl] cyclopropylmethylamine (Intermediate 1-35)
[255] IR (neat): 2901, 1450 cm ^-1
[256] N- [2- (1-adamantyl) ethyl] -3,3,3-trifluoropropylamine hydrochloride (Intermediate 1-36)
[257] IR (KBr): 2910, 2849, 2767, 2598, 2457 cm ^-1
[258] mp: 300.0-310.0 ° C
[259] 1- [2- (1-adamantyl) ethyl] -2- (t-butoxycarbonyl) hydrazine (intermediate 1-37)
[260] IR (KBr): 3288, 2899, 1705 cm ^-1
[261] mp: 73.5-81.0 ° C.
[262] N- (t-butoxycarbonyl) -N-methyl-N'-phenethylethylenediamine (intermediate 1-38)
[263] IR (neat): 3326, 3025, 2975, 2930, 1694, 1454 cm ^-1
[264] N- (t-butoxycarbonyl) -N-methyl-N'-pentylethylenediamine (intermediate 1-39)
[265] IR (neat): 2958, 2929, 1694, 1457 cm ^-1
[266] N- (benzyloxycarbonyl) -N-methyl-N'-phenethylethylenediamine (intermediate 1-40)
[267] IR (neat): 3309, 3027, 2936, 2824, 1698, 1454 cm ^-1
[268] N- (benzyloxycarbonyl) -N-methyl-N'-pentylethylenediamine (intermediate 1-41)
[269] IR (neat): 2928, 2858, 1703, 1455 cm ^-1
[270] 2-cyclohexyl-N- (2-methoxyethyl) ethylamine hydrochloride (Intermediate 1-42)
[271] IR (KBr): 2923, 2855, 2784, 2478, 2444 cm ^-1
[272] mp: 205.0-208.0 ° C
[273] N-ethyl-3,4,5-trimethoxyphenethylamine (intermediate 1-43)
[274] IR (neat): 3300, 2936, 2828, 1588, 1508, 1457, 1419, 1331, 1236, 1126, 1008 cm ^-1
[275] 5- [2- (isopentylamino) ethyl] imidazole dihydrochloride (Intermediate 1-44)
[276] IR (KBr): 2806, 2467, 1619, 1604, 1446, 1347, 1089, 914, 827, 735, 627, 622 cm ^-1
[277] mp: 235.2-238.0 ° C.
[278] N-cyclohexyl-3,4-dimethoxyphenethylamine (intermediate 1-45)
[279] IR (neat): 2928, 2852, 1591, 1515, 1463, 1449, 1416, 1261, 1236, 1155, 1139, 1029, 802, 761 cm ^-1
[280] bp: 170 ℃ / 210 Pa
[281] N-cyclopropyl-3,4,5-trimethoxyphenethylamine (intermediate 1-46)
[282] IR (neat): 3304, 2932, 2832, 1588, 1505, 1459, 1418, 1332, 1236, 1126, 1009 cm ^-1
[283] N '-[2- (1-adamantyl) ethyl] -N- (t-butoxycarbonyl) -N-methyl-1,3-propanediamine (Intermediate 1-47)
[284] IR (neat): 3308, 2902, 2845, 1698, 1480 cm ^-1
[285] N-cyclohexyl (phenyl) methyl-3- (4-methoxyphenyl) propylamine hydrochloride (Intermediate 1-48)
[286] IR (KBr): 2928, 2857, 2765, 1592, 1510, 1455, 1230, 1064, 1033, 817 cm ^-1
[287] mp: 187.5-189.5 ° C.
[288] N-diphenylmethyl-3-phenylpropylamine (intermediate 1-49)
[289] IR (neat): 3024, 2931, 1601, 1493, 1452 cm ^-1
[290] N-pentyl-3-phenylpropylamine hydrochloride (Intermediate 1-50)
[291] IR (KBr): 3027, 2955, 2870, 2780, 2492, 2413 cm ^-1
[292] mp: 230.0-238.0 ° C
[293] N-acetyl-N '-[2- (1-adamantyl) ethyl] ethylenediamine hydrochloride (Intermediate 1-51)
[294] IR (neat): 2897, 2845, 2361, 1826, 1707, 1567 m ^-1
[295] mp: 245.0-247.0 ° C.
[296] N-isopentyl-3,3,3-trifluoropropylamine hydrochloride (Intermediate 1-52)
[297] IR (KBr): 2961, 2800, 1253, 1173 m ^-1
[298] mp: above 288 ° C
[299] N- [2- (1-adamantyl) ethyl] -2,2,2-trifluoroethylamine hydrochloride (Intermediate 1-53)
[300] IR (KBr): 2904, 2849, 1273, 1233, 1176, 1145 m ^-1
[301] mp: 263.0-265.0 ° C.
[302] 3-cyclohexyl-N-propylpropylamine hydrochloride (Intermediate 1-54)
[303] IR (KBr): 2924, 2854, 2779 m ^-1
[304] mp: 234.6-235.4 ° C.
[305] N '-[3- (1-adamantyl) propyl] -N- (t-butoxycarbonyl) -N-methylethylenediamine (intermediate 1-55)
[306] ¹ H-NMR (400 MHz, CDCl ₃ ) δ 0.99-1.10 (m, 2H), 1.32-1.52 (m, 17H), 1.55-1.65 (m, 4H), 1.70 (d, J = 11.8 Hz, 3H ), 1.93 (s, 3H), 2.58 (t, J = 7.2 Hz, 2H), 2.77 (br, 2H), 2.91 (s, 3H), 3.33 (br, 2H)
[307] Intermediate Preparation Example 2
[308] 4- (3-aminopropyl) pyridine (Intermediate 2-1)
[309] N- [3- (4-pyridyl) propyl] phthalimide (67.1 g, 252 mmol), methanol (504 ml) and hydrazine-hydrate (18.3 ml, 378 mmol) were mixed and heated to reflux for 3 hours. After cooling, insoluble matters were separated by filtration, and the filtrate was concentrated under reduced pressure. Chloroform (1 L) and 4N aqueous sodium hydroxide solution (500 ml) were added to the residue, and the organic layer was dried over sodium sulfate after separation. Concentration under reduced pressure and distillation under reduced pressure yielded 20.5 g (60%) of the target compound as a colorless oil.
[310] IR (neat): 3362, 2933, 1603 cm ^-1
[311] bp: 76.0-79.0 ℃ / 40 Pa
[312] The following compounds were obtained by the same operation as in Intermediate Production Example 2.
[313] 3- (4-pyridyl) -2-propenylamine (intermediate 2-2)
[314] IR (neat): 3280, 3024, 1599 cm ^-1
[315] 2- (4-pyridyloxy) ethylamine (intermediate 2-3)
[316] IR (KBr): 3298, 3102, 1610, 1216, 1049 cm ^-1
[317] mp: 108.0-111.5 ° C.
[318] 3- (4-quinolyl) -2-propenylamine (intermediate 2-4)
[319] IR (neat): 3270, 2944, 1585, 1568, 1508 cm ^-1
[320] Intermediate Preparation Example 3
[321] 2- (1-adamantyl) -N-methylethylamine (intermediate 3-1)
[322] To a solution of lithium aluminum hydride (569 mg, 15.0 mmol) in diethyl ether (34.0 ml) under ice-cooling, a solution of tetrahydrofuran (15.0 ml) in 1-adamantane acetate N-methylamide (1.54 g, 7.45 mmol) It dripped in 5 minutes. After heating under reflux for 6 hours, the mixture was stirred under ice-cooling again, ethyl acetate was added to treat excess lithium aluminum hydride, and the reaction solution was extracted twice with 1N hydrochloric acid (50 ml). The extract was made basic by the addition of 4N aqueous sodium hydroxide solution, and extracted with diethyl ether (80 ml). The organic layer was washed with saturated aqueous sodium chloride solution (60 ml) and then dried over magnesium sulfate. The solvent was evaporated off under reduced pressure to obtain 890 mg (66%) of the target compound.
[323] IR (neat): 2902, 2845, 1449 cm ^-1
[324] The following compounds were obtained by the same operation as in Intermediate Production Example 3.
[325] The compound may also be used as a hydrochloride salt with 4N ethyl acetate acetate solution.
[326] 2- (1-adamantyl) -N-ethylethylamine hydrochloride (Intermediate 3-2)
[327] IR (KBr): 2896, 2847, 2753, 2468, 1610 cm ^-1
[328] mp: 230-245 ° C.
[329] N-methyl-3- (4-pyridyl) propylamine (intermediate 3-3)
[330] IR (neat): 3292, 2934, 1602 cm ^-1
[331] 1-adamantyl-N-propylmethylamine hydrochloride (Intermediate 3-4)
[332] IR (KBr): 2905, 1584, 1451 cm ^-1
[333] mp: 340 ° C.
[334] 2- (1-adamantyl) -N-methylethylamine hydrochloride (Intermediate 3-5)
[335] IR (KBr): 3422, 2900, 2846, 2676, 2450, 1630 cm ^-1
[336] mp: 200-220 ° C
[337] 3- (1-adamantyl) -N-propylpropylamine hydrochloride (Intermediate 3-6)
[338] IR (KBr): 2899, 2467, 1449 cm ^-1
[339] mp: 159.5-162.0 ° C.
[340] 1-adamantyl-N-pentylmethylamine hydrochloride (Intermediate 3-7)
[341] IR (KBr): 2916, 2603, 2509, 2418, 1477 cm ^-1
[342] mp: 170-235 ° C
[343] N- [3- (1-adamantyl) propyl] pentylamine hydrochloride (Intermediate 3-8)
[344] IR (KBr): 2901, 2847, 1466, 1453 cm ^-1
[345] mp: 199-224 ° C.
[346] N- [2- (1-adamantyl) ethyl] -4,4,4-trifluorobutylamine hydrochloride (Intermediate 3-9)
[347] IR (KBr): 3422, 2908, 2852, 2770, 2518, 1452, 1255, 1148 cm ^-1
[348] mp: 243-274 ° C.
[349] N- [2- (1-adamantyl) ethyl] -5,5,5-trifluoropentylamine (intermediate 3-10)
[350] IR (neat): 2903, 2846, 1450, 1255, 1142 cm ^-1
[351] N-'[3- (1-adamantyl) propyl] butylamine hydrochloride (Intermediate 3-11)
[352] IR (KBr): 2904, 2847, 2756, 1453 cm ^-1
[353] mp: 275.0-276.8 ° C
[354] 3- (1-adamantyl) -N- (2,2,2-trifluoroethyl) propylamine hydrochloride (Intermediate 3-12)
[355] IR (KBr): 2902, 2850, 2739, 1274, 1258, 1176, 1139 cm ^-1
[356] mp: 262.0-268.0 ° C
[357] 4- (1-adamantyl) -N-ethylbutylamine hydrochloride (Intermediate 3-13)
[358] IR (KBr): 2901, 2847, 2457, 1451 cm ^-1
[359] mp: 224-230 ° C.
[360] 4- (1-adamantyl) -N-propylbutylamine hydrochloride (Intermediate 3-14)
[361] IR (KBr): 2899, 2848, 2751, 2410, 1451 cm ^-1
[362] mp: 234-249 ° C.
[363] N- (1-adamantyl) -N'-propylethylenediamine hydrochloride (Intermediate 3-15)
[364] IR (KBr): 2927, 2719, 2508, 2429, 1471 cm ^-1
[365] mp: 288.5-289.5 ° C.
[366] Intermediate Preparation Example 4
[367] 3- [N- [2- (1-adamantyl) ethyl] amino] propionic acid t-butylester hydrochloride (Intermediate 4-1)
[368] 2- (1-adamantyl) ethylamine hydrochloride (1.0 g, 4.6 mmol) was dissolved in ethanol (10 ml), triethylamine (0.65 ml, 4.6 mmol) and t-butyl acrylate (0.75 ml) under ice cooling. , 5.1 mmol) was added, and the mixture was returned to room temperature and stirred overnight. The reaction solution was concentrated under reduced pressure, 1N aqueous sodium hydroxide solution (30 ml) and ethyl acetate (50 ml) were added to the residue. The ethyl acetate layer was washed with water (50 ml) and saturated aqueous sodium chloride solution (50 ml), and dried over anhydrous magnesium sulfate. After concentration under reduced pressure, purification was performed by silica gel column chromatography. The obtained oily substance (0.50 g, 1,6 mmol) was melt | dissolved in diethyl ether (20 ml), and solid was precipitated when 4N ethyl-hydrogen acetate solution (1.0 ml, 4.0 mmol) was added under ice-cooling. Filtration of this with diethyl ether gave 0.33 g (23%) of the target compound.
[369] IR (KBr): 2902, 2846, 1733, 1166 cm ^-1
[370] mp: 210 ° C.
[371] The following compounds were obtained by the same operation as in Intermediate Production Example 4. In addition, the target compound may not be isolated as a hydrochloride salt.
[372] 3- [N- (2-cyclohexylethyl) amino] propionic acid methyl ester hydrochloride (Intermediate 4-2)
[373] IR (KBr): 2924, 2853, 2792, 1736, 1455, 1439 cm ^-1
[374] mp: 185.0-187.5 ° C.
[375] 3- [N- (2-cyclohexylethyl) amino] propionic acid t-butyl ester (Intermediate 4-3)
[376] IR (neat): 2977, 2922, 2850, 1728, 1449 cm ^-1
[377] 3- [N- [3- (4-pyridyl) propyl] amino] propionic acid t-butylester hydrochloride (Intermediate 4-4)
[378] IR (neat): 3322, 2977, 2933, 1724, 1602, 1367, 1153 cm ^-1
[379] Intermediate Preparation Example 5
[380] 5- (4-pyridyl) valeric acid (intermediate 5-1)
[381] Brominated (benzyloxycarbonylmethyl) triphenylphosphonium (4.60 g, 9.36 mmol), N-N-dimethylformamide (17 ml) in β- (4-pyridyl) acroleinoxalate (1.90 g, 8.51 mmol) Was added and stirred under ice cooling. Potassium carbonate (4.70 g, 34.0 mmol) was added and the reaction solution was brought to room temperature. After stirring overnight, the mixture was diluted with ethyl acetate (100 ml), washed twice with water (100 ml) and saturated brine (50 ml). After drying over sodium sulfate, ethyl acetate was evaporated off under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain 2.29 g (quantitative) of 5- (4-pyridyl) valeric acid-2,4-diebenzyl ester as a pale yellow oil.
[382] Subsequently, methanol (42 ml) and acetic acid (1.0 ml, 18 mmol) were added to 5- (4-pyridyl) valeric acid-2,4-dienebenzyl ester (2.25 g, 8.48 mmol), and nitrogen gas was added for 10 minutes. Palladium hydroxide on carbon was added to the catalyst amount and stirred overnight at room temperature under a hydrogen atmosphere. After filtering out insoluble matters by Celite filtration, the filtrate was concentrated under reduced pressure. Ethyl acetate (50 ml) was added to the solidified residue, and the mixture was stirred at room temperature for 3 hours. Filtration of the crystals gave 1.00 g (66%) of the target compound as pale yellow crystals.
[383] IR (KBr): 2943, 1719, 1636, 1605 cm ^-1
[384] mp: 155.0-180.0 ° C.
[385] Intermediate Preparation Example 6
[386] 3- [N- (2-cyclohexylethyl) amino] propionic acid amide hydrochloride (Intermediate 6-1)
[387] Under ice-cooling, trifluoroacetic acid (6 ml) was added to 3- [N- (2-cyclohexylethyl) amino] propionic acid t-butyl ester (2.0 g, 7.8 mmol) of the intermediate 4-3. After stirring overnight, the mixture was concentrated under reduced pressure. To the residue was added 4N ethyl acetate acetate solution, concentrated under reduced pressure, and the resulting crystals were filtered off with diethyl ether to obtain 1.5 g (96%) of 3- [N- (2-cyclohexylethyl) amino] propionate. there was.
[388] Subsequently, tetrahydrofuran (8 ml) was added to 3- [N- (2-cyclohexylethyl) amino] propionate (1.0 g, 4.2 mmol), and it stirred at room temperature. Di-t-butyl ester carbonate (1.1 g, 5.1 mmol) and triethylamine (1.3 ml, 9.3 mmol) were added, followed by stirring overnight, and 5% aqueous citric acid solution (10 ml) was added thereto. After extraction with chloroform (60 ml), the organic layer was washed with saturated brine (20 ml). After drying over magnesium sulfate, the mixture was concentrated under reduced pressure. Purification of the residue by silica gel column chromatography yielded 0.79 g (62%) of 3- [N- (t-butoxycarbonyl) -N- (2-cyclohexylethyl) amino] propionic acid as a colorless oil.
[389] Then, tetrahydrofuran anhydride (7 ml) was added to 3- [N- (t-butoxycarbonyl) -N- (2-cyclohexylethyl) amino] propionic acid (0.59 g, 2.0 mmol), and -78 ° C. Stirred at. N-methylmorpholine (0.22 ml, 2.0 mmol) was then added a solution of tetrahydrofuran (3 ml) of isobutyl chloroformate (0.38 ml, 2.9 mmol). After 1 hour, 28% aqueous ammonia solution (6.0 ml, 9.8 mmol) was added, followed by stirring for 1.5 hours. Chloroform (50 ml) was added to room temperature, followed by washing with saturated sodium bicarbonate water (20 ml) and saturated brine (20 ml). After drying over magnesium sulfate, the residue was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 0.34 g (58) of 3- [N- (t-butoxycarbonyl) -N- (2-cyclohexylethyl) amino] propionamide. %) Was obtained as colorless crystals.
[390] Then, a solution of 4N hydrogen chloride 1,4-dioxane (3.1 ml) in 3- [N- (t-butoxycarbonyl) -N- (2-cyclohexylethyl) amino] propionic acid amide (0.37 g, 1.2 mmol) Was added and stirred overnight at room temperature. After concentration under reduced pressure, diisopropyl ether was added to the resulting solid and filtered to obtain 0.30 g (quantitative) of the target compound as colorless crystals.
[391] IR (KBr): 3386, 3196, 2921, 2852, 2808, 1705, 1656, 1452 cm ^-1
[392] mp: 165.0 ° C.
[393] Intermediate Preparation Example 7
[394] Di-5-hexenylamine (intermediate 7-1)
[395] N, N-dimethylformamide (28 ml) was added to 3-aminopropionitrile (0.98 g, 14 mmol), and it stirred at room temperature. 6-bromo-1-hexene (5.0 g, 31 mmol), sodium iodide (11 g, 73 mmol) and potassium carbonate (5.8 g, 42 mmol) were added and stirred overnight. Dilution with diethyl ether (100 ml) was followed by washing with water (100 ml, twice) and saturated brine (50 ml). After drying over sodium sulfate, the organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 2.2 g (66%) of 3- (di-5-hexenyl) aminopropionitrile as a colorless oil.
[396] Subsequently, ethanol (8.6 ml) and potassium hydroxide (0.85 g, 13 mmol) were added to 3- (di-5-hexenyl) aminopropionitrile (2.0 g, 8.6 mmol) and heated to reflux for 7.5 hours. After cooling, water (150 ml) and chloroform (150 ml) were added thereto, and the organic layer was dried over sodium sulfate. After concentration under reduced pressure, the residue was purified by basic silica gel column chromatography to obtain 0.32 g (21%) of the titled compound as a pale yellow oil.
[397] IR (neat): 3076, 2976, 2928, 2856, 1679, 1640 cm ^-1
[398] The following compounds were obtained by the same operation as in Intermediate Production Example 7.
[399] Di-7-octenylamine (intermediate 7-2)
[400] IR (neat): 3075, 2976, 2926, 2854, 1640 cm ^-1
[401] Intermediate Preparation Example 8
[402] N- [2- (1-adamantyloxy) ethyl] propylamine hydrochloride (Intermediate 8-1)
[403] 2- (propylamino) ethanol (2.4 g, 23 mmol), 1-bromoadamantane (0.50 g, 2.3 mmol) and triethylamine (0.32 ml, 2.3 mmol) were mixed and heated at 100 ° C. for 2 hours, 130 It stirred at 5 degreeC for 5 hours and 150 degreeC for 3 hours. After cooling, ethyl acetate (50 ml) was added, followed by washing twice with water (50 ml) and saturated brine (30 ml). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was separated by silica gel column chromatography, 4N ethyl hydrogen acetate acetate solution (2 ml) was added thereto, concentrated under reduced pressure, and the resulting crystals were filtered out with ethyl acetate to give 0.16 g (25%) of the target compound as colorless crystals.
[404] IR (KBr): 3544, 2907, 2502, 1584 cm ^-1
[405] mp: 232.0-232.7 ° C.
[406] Intermediate Preparation Example 9
[407] 2-propylaminoacetic acid N- (1-adamantyl) amide (intermediate 9-1)
[408] Ethanol (36 ml) was added to bromoacetic acid (5.00 g, 36.0 mmol), followed by stirring under ice cooling. Propylamine (14.8 ml, 180 mmol) was added for 1 minute, and the mixture was stirred at an external temperature of 80 ° C. for 2.5 hours. 4N aqueous sodium hydroxide solution (27 ml) was added thereto, concentrated under reduced pressure, water (27 ml) and tetrahydrofuran (30 ml) were added thereto, followed by stirring at room temperature. A tetrahydrofuran (6 ml) solution of di-t-butyl carbonate (9.43 g, 43.2 mmol) was added, and after 15 minutes, citric acid hydrate was added to make it slightly acidic. After extraction with ethyl acetate (150 ml), the mixture was washed with water (100 ml) and saturated brine (50 ml) in that order. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was separated by silica gel column chromatography to give 5.06 g (65%) of 2- [N- (t-butoxycarbonyl) -N-propylamino] acetic acid as a colorless solid.
[409] Then methylene chloride (208 ml) in 2- [N- (t-butoxycarbonyl) -N-propylamino] acetic acid (4.52 g, 20.8 mmol), 1-adamantanamine (3.46 g, 22.9 mmol) Was added and stirred at room temperature. N, N-diisopropylethylamine (7.25 ml, 41.6 mmol) followed by O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate ( 8.71 g, 22.9 mmol) was added and the mixture was stirred overnight. The reaction solution was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography. 2- [N '-(t-butoxycarbonyl) -N'-propylamino] acetic acid N- (1-adamantyl) amide 7.88 g (quantitative) was obtained as a colorless oil. The obtained oily substance solidified at room temperature.
[410] Subsequently, 55 mL of 4N ethyl acetate acetate solution (55 ml) in 2- [N '-(t-butoxycarbonyl) -N'-propylamino] acetic acid N- (1-adamantyl) amide (7.68 g, 21.9 mmol) And 0.22 mo1) were added, and it stirred at room temperature for 1 hour. Ethyl acetate was filtered off and the resulting crystals were washed with ethyl acetate to give 5.97 g (95%) of the target compound as colorless crystals.
[411] IR (KBr): 3272, 2906, 2848, 2589, 1676, 1562 cm ^-1
[412] mp: 278.0-279.2 ° C
[413] Intermediate Preparation Example 10
[414] N- (t-butoxycarbonyl) -2- (4-pyridyloxy) ethylamine (intermediate 10-1)
[415] Under ice-cooling, di-t-butyldicarbonate (380 mg, 1.74 mmol) and triethylamine (240 μI, 1.74 mmol) were added to a tetrahydrofuran (5 ml) solution of intermediate 2-4 (200 g, 1.45 mmol). Was added, and it stirred at room temperature for 25 minutes. The reaction solution was evaporated off under reduced pressure, and then partitioned into ethyl acetate (50 ml) and saturated aqueous sodium hydrogen carbonate solution (50 ml). The aqueous layer was further extracted with chloroform (50 ml), and the combined organic layers were dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was purified by silica gel column chromatography to obtain 70 mg (20.2%) of the target compound. there was.
[416] IR (neat): 3230, 2976, 1706, 1596 cm ^-1
[417] Intermediate Preparation Example 11
[418] (RS) -2-methyl-3- (4-pyridyl) propylamine (intermediate 11-1)
[419] N, N-dimethylformamide (143 ml) was added to sodium hydride (5.36 g, 134 mmol) under nitrogen atmosphere, and it stirred under ice-cooling. A solution of methylmalonic acid diethyl ester (11.7 g, 67.1 mmol) in N, N-dimethylformamide (40 ml) was added dropwise for 5 minutes, and after 10 minutes, 4-chloro picoyl hydrochloride (10.0 g, 61.0 mmol) was added little by little for 5 minutes. It was added over to room temperature. After 1 hour, saturated sodium bicarbonate water (500 ml) was added, followed by extraction with diethyl ether (400 ml). The organic layer was washed with water (100 ml) saturated brine (50 ml) and dried over magnesium sulfate. When concentrated under reduced pressure, 17.2 g (quantitatively, including sodium hydride oil) of 2-methyl-2- (4-pyridylmethyl) malonic acid diethyl ester was obtained as a brown oil.
[420] Subsequently, 6N hydrochloric acid (96.8 ml, 581 mmol) was added to 2-methyl-2- (4-pyridylmethyl) malonic acid diethyl ester (17.2 g, 64.6 mmol), and it heated and refluxed overnight. After cooling, the mixture was washed with hexane (100 ml) to remove sodium hydride oil contained in 2-methyl-2- (4-pyridylmethyl) malonic acid diethyl ester and concentrated under reduced pressure. The resulting crystals were filtered out with ethyl acetate to give 10.7 g (82%) of 2-methyl-3- (4-pyridyl) propionic acid as pale pink crystals.
[421] Then in 2-methyl-3- (4-pyridyl) propionic acid (1.69 g, 10.2 mmol), chloroform (8 ml), thionyl chloride (2.2 ml, 30.6 mmol), N, N-dimethylformamide (1 drop) Was added and heated to reflux for 1 hour with stirring. After concentration under reduced pressure, chloroform (8 ml) was added, and slowly added to an aqueous 28% ammonia solution stirred under ice-cooling. After 10 minutes, the mixture was brought to room temperature and stirred overnight. Ethyl acetate (100 ml) was added after concentration under reduced pressure, and the resulting insoluble matter was filtered off. The filtrate was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography. The resulting crystals were filtered out with diethyl ether to give 0.72 g (43%) of 2-methyl-3- (4-pyridyl) propionamide. Obtained as pale yellow crystals.
[422] Subsequently, anhydrous diethyl ether (20 ml) was added to lithium aluminum hydride (0,45 g, 12 mmol) in a nitrogen atmosphere, followed by stirring under ice cooling. Anhydrous methylene chloride (2.0 ml) solution of 2-methyl-3- (4-pyridyl) propionic acid amide (0.68 g, 4.1 mmol) was added dropwise for 5 minutes, and stirred overnight at room temperature. It was made to ice-cool again, ethyl acetate (5 ml) was added slowly, Then, 1N sodium hydroxide aqueous solution was added slowly at first, and 100 ml of whole quantity was added. After extraction with chloroform (100 ml), the organic layer was dried over sodium sulfate and concentrated under reduced pressure to give 0.56 g (90%) of the target compound as a pale yellow oil.
[423] IR (neat): 3293, 2957, 2925, 1602 cm ^-1
[424] The following compounds were obtained by the same operation as in Intermediate Production Example 11. Moreover, the optically active substance was obtained by optically dividing using the optically active acid.
[425] 2- (4-pyridylmethyl) butylamine (intermediate 11-2)
[426] IR (neat): 3296, 3025, 2960, 2874, 1602 cm ^-1
[427] 2-benzyl-3- (4-pyridyl) propylamine (intermediate 11-3)
[428] IR (neat): 3296, 3062, 3025, 1602 cm ^-1
[429] 2,2-bis (4-pyridylmethyl) ethylamine (Intermediate 11-4)
[430] IR (neat): 3290, 3026, 2924, 1602, 1557 cm ^-1
[431] (-)-2-methyl-3- (4-pyridyl) propylamine (intermediate 11-5)
[432] IR (neat): 3362, 3301, 2958, 1603 cm ^-1
[433] [α] ²⁰ _D : -10.6 ° (MeOH, C1.0)
[434] (+)-2-methyl-3- (4-pyridyl) propylamine (intermediate 11-6)
[435] IR (neat): 3362, 3294, 2958, 1603 cm ^-1
[436] [α] ²⁰ _D : + 9.9 ° (MeOH, C1.0)
[437] Intermediate Preparation Example 12
[438] 3- (4-quinolyl) propylamine (intermediate 12-1)
[439] 10% of the catalytic amount in a methanol (3 ml) solution of 3- (4-quinolyl) -2-propenylamine (Intermediate 2-4) (188 mg, 1.02 mmol) obtained in Intermediate Preparation Example 2 under room temperature nitrogen atmosphere. Palladium on carbon was added and the mixture was stirred overnight under a hydrogen atmosphere. The reaction solution was filtered through celite, and the residue obtained by evaporation of the solvent under reduced pressure was partitioned between ethyl acetate (30 ml) and saturated aqueous ammonium chloride solution (30 ml). Aqueous 4N sodium hydroxide solution (30 ml) was added to the aqueous layer, followed by extraction with chloroform (100 ml), and the obtained organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated off under reduced pressure to obtain 145 mg (76.3%) of the target compound.
[440] IR (neat): 3350, 2938, 1591, 1510 cm ^-1
[441] Intermediate Preparation Example 13
[442] 3- (4-pyridyl) butylamine (intermediate 13-1)
[443] N, N-dimethylformamide (33 ml) was added to 4-acetylpyridine (2.00 g, 16.5 mmol) and brominated (benzyloxycarbonyl) triphenylphosphonium (8.94 g, 18.2 mmol), followed by stirring under ice cooling. Potassium carbonate (9.12 g, 66.0 mmol) was added, it was made into 70 degreeC of external temperature, and it stirred overnight. After dilution with diethyl ether (100 ml), the mixture was washed with water (100 ml, twice) and saturated brine (50 ml) in that order. After drying over magnesium sulfate, the mixture was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain 1.77 g (42%: mixture of E and Z forms) of 3- (4-pyridyl) -2-butene acid as a pale yellow oil.
[444] Then, methanol (31 ml) and acetic acid (0.71 ml, 12.4 mmol) were added to 3- (4-pyridyl) -2-butene acid benzyl ester (1.75 g, 6.20 mmol), and nitrogen gas was vented at room temperature for 10 minutes. . A catalytic amount of 10% -carbonaceous palladium was added and stirred overnight at room temperature under hydrogen atmosphere. After the insoluble matter was filtered off, the filtrate was concentrated under reduced pressure. The resulting crystals were filtered out with acetone to give 0.61 g (60%) of 3- (4-pyridyl) butyric acid as pale yellow crystals.
[445] To 3- (4-pyridyl) butyric acid (0.60 g, 3.6 mmol) were added chloroform (5 ml), thionyl chloride (0.80 ml, 11 mmol) and N, N-dimethylformamide (1 drop). It heated and refluxed for 1 hour, stirring. After concentration under reduced pressure, chloroform (5 ml) was added, and slowly added to the saturated ammonia / tetrahydrofuran (5 ml) solution stirred under ice-cooling. After 2.5 hours, the insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain 0.34 g of a mixture of 3- (4-pyridyl) butyric acid amide and its olefin oxide as light yellow crystals.
[446] Then, anhydrous ether (8 ml) was added to lithium aluminum hydride (0.16 g, 4.2 mmol) in nitrogen atmosphere, and it stirred under ice-cooling. Anhydrous methylene chloride (8 ml) solution of 3- (4-pyridyl) butyric acid amide (0.22 g, 1.4 mmol) was added dropwise for 2 minutes, brought to room temperature, and stirred overnight. Ethyl acetate (1 ml) and 1N aqueous sodium hydroxide solution (20 ml) were added, followed by extraction with chloroform (50 ml). The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.15 g (75%) of the target compound as a pale yellow oil.
[447] IR (neat): 3350, 2963, 2873, 1601 cm ^-1
[448] Intermediate Preparation 14
[449] N- (4-pyridyl) ethylenediamine (intermediate 14-1)
[450] Ethylenediamine (10.4 ml, 155 mmol) was added to 4-bromopyridine hydrochloride (3.00 g, 15.5 mmol) in nitrogen atmosphere, and it heated and refluxed for 1.5 hours. At room temperature, potassium carbonate (8.57 g, 62.0 mmol) was added, the mixture was stirred for 10 minutes, and then the solids were separated by filtration, and the solids were washed with toluene and 2-propanol. The filtrate was concentrated under reduced pressure, the residue was separated and purified by basic silica gel column chromatography, and the resulting solid was filtered out with diisopropyl ether to give 1.63 g (77%) of the target compound as a pale yellow solid.
[451] IR (KBr): 3320, 3240, 3028, 2930, 1615 cm ^-1
[452] mp: 114.0-116.5 ° C.
[453] Intermediate Preparation Example 15
[454] 4- (3-aminobutyl) pyridine (Intermediate 15-1)
[455] Anhydrous N, N-dimethylformamide (41 ml) was added to sodium hydride (2.81 g, 70.3 mmol) under a nitrogen atmosphere, and the mixture was stirred under ice cooling. N, N-dimethylformamide (20 ml) solution of acetic acetic acid t-butyl ester (6.33 g, 40.0 mmol) was added dropwise for 10 minutes, and further 10 minutes under nitrogen stream, 4- (chloromethyl) pyridine hydrochloride (5.00 g) , 30.5 mmol) was added little by little for 3 minutes to room temperature. After 2 hours, saturated sodium bicarbonate water (150 ml) was added, followed by extraction with ethyl acetate (100 ml). The organic layer was washed with water (100 ml) and saturated brine (50 ml) and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the residue was separated and purified by silica gel column chromatography to obtain 1.34 g (18%) of 2-acetyl-3- (4-pyridyl) propionate ethyl ester as a pale yellow oil.
[456] Subsequently, 6N hydrochloric acid (8 ml) was added to 2-acetyl-3- (4-pyridyl) propionic acid ethyl ester (1.20 g, 4,81 mmol), and the mixture was heated to reflux for 1.5 hours. After concentration under reduced pressure, 2-propanol (10 ml) was added, and the mixture was concentrated under reduced pressure again. Ethyl acetate was added to the resulting solid and filtered off to obtain 0.79 g (89%) of 4- (4-pyridyl) -2-butanone as a pale yellow solid.
[457] Subsequently, water (12, ml) and tetrahydrofuran (1.2 ml) were added to 4- (4-pyridyl) -2-butanone (736 mg, 3.96 mmol), and the mixture was stirred at room temperature. Sodium carbonate (483 mg, 4.56 mmol) and hydroxylamine hydrochloride (358 mg, 5.15 mmol) were added, and the mixture was stirred for 1.5 hours and ethyl acetate (50 ml) was added and diluted. Sodium bicarbonate was added, the solution was separated and washed with brine (10 ml). The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. Cyclohexane was added to the resulting crystals to obtain 584 mg (90%) of 4- (4-pyridyl) -2-butanone oxime as pale yellow crystals.
[458] Subsequently, anhydrous ether (19 ml) was added to lithium aluminum hydride (257 mg, 6.77 mmol) in a nitrogen atmosphere, followed by stirring under ice cooling. An ether (15 ml) solution of 4- (4-pyridyl) -2-butanone oxime (556 mg, 3.38 mmol) was added dropwise for 7 minutes, and stirred overnight at room temperature. After refluxing for 2 days, the mixture was further stirred under ice cooling. Ethyl acetate was slowly added and 1N aqueous sodium hydroxide solution (first slowly, 20 ml in total) was added. Chloroform (80 ml) was added, the insolubles were filtered off with celite, and after separation, the chloroform was concentrated under reduced pressure. The residue and the aqueous layer were combined, tetrahydrofuran (20 ml) was added, and the mixture was stirred at room temperature. Di-t-butyl ester carbonate (1.48 g, 6.78 mmol) was added and the mixture was stirred overnight. Chloroform (50 ml) was added, followed by extraction, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography. 4N ethyl hydrogen chloride acetate solution (3 ml) and ethanol (1 ml) were added to the residue, which was stirred at room temperature. After 3 hours, the residue was concentrated under reduced pressure, chloroform (5 ml), methanol (5 ml) and triethylamine (1 ml) were added to the residue, followed by concentration under reduced pressure, and the residue was separated and purified by basic silica gel column chromatography. mg (32%) was obtained as a brown oil.
[459] IR (neat): 3354, 3280, 2958, 2925, 2866, 1602 cm ^-1
[460] The following compounds were obtained by the same operation as in Intermediate Production Example 15.
[461] 1,2-dimethyl-3- (4-pyridyl) propylamine (intermediate 15-2)
[462] IR (neat): 3360, 3287, 2963, 2930, 2876, 1602 cm ^-1
[463] 1-ethyl-3- (4-pyridyl) propylamine (intermediate 15-3)
[464] IR (neat): 3357, 2963, 2934, 2875, 1605 cm ^-1
[465] Intermediate Preparation Example 16
[466] 2,2-dimethyl-3- (4-pyridyl) propylamine (intermediate 16-1)
[467] In a nitrogen atmosphere, a tetrahydrofuran (150 ml) solution of diisopropylamine (10.0 ml, 71.5 mmol) was cooled to -78 ° C, and a hexane solution (1.6 N) of butyllithium was added dropwise over 10 minutes. After cooling for 20 minutes with ice-cold water, the mixture was again cooled to -78 ° C, and isobutyronitrile (3.03 ml, 33.3 mmol) was added dropwise over 5 minutes. 4-pyridinecarboxyaldehyde (3.18 ml, 33.3 mmol) was further added dropwise over 5 minutes, and stirred for 1 hour and 20 minutes. Water (100 ml) was added and the reaction mixture was extracted with ethyl acetate (200 ml) with a continuous extraction device for 3 days. The resulting organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the obtained solid was filtered out with diethyl ether to obtain 4.20 g (71) of 3-hydroxy-2,2-dimethyl-3- (4-pyridyl) propionitrile. , 6%) was obtained as a colorless solid.
[468] Triethylamine (1.57 ml, 11.3 mmol) in dichloromethane (20 ml) solution of 3-hydroxy-2,2-dimethyl-3- (4-pyridyl) propionitrile (1.00 g, 5.67 mmol) at room temperature. ). P-toluenesulfonyl chloride (1.30 g, 6.80 mmol) was further added, and it overheated and stirred at 50 degreeC for 3 days. After allowing to cool, the reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography to give 699 mg (37.4%) of 2,2-dimethyl-3- (4-pyridyl) -3- (p-tolylsulfonyloxy) propionitrile. ) Was obtained as a pale yellow solid.
[469] Lithium aluminum hydride (345 mg, 9.10 mmol) was added under a nitrogen atmosphere, and anhydrous diethyl ether (10 ml) was added dropwise under ice water cooling. Then, a tetrahydrofuran (10 ml) solution of 2,2-dimethyl-3- (4-pyridyl) -3- (p-tolylsulfonyloxy) propionitrile (600 mg, 1.82 mmol) was added dropwise. At room temperature, the mixture was stirred overnight, and under ice water cooling, water (324 µl), 15% aqueous sodium hydroxide solution (324 µl), and water (972 µl) were sequentially added while vigorously stirring the reaction mixture. After drying over anhydrous magnesium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography, the target compound (83.0 mg, 0.505 mmol, 28%) was obtained as a pale yellow oil.
[470] IR (neat): 3290, 3074, 2960, 1652, 1602, 1417 cm ^-1
[471] Intermediate Preparation 17
[472] (RS) -2-methyl-3- (4-pyridyl) propanol (intermediate 17-1)
[473] 2-methyl-3- (4-pyridyl) propionic acid (136 g, 0.676 mol) obtained in the synthesis of Intermediate Preparation Example 11 was dissolved in tetrahydrofuran (1500 m 1), and cooled with ice water to give sodium borohydride (56.2). g, 1.49 mol) was added. After 30 minutes, a mixture of iodine (85.8 g, 0.338 mol) and tetrahydrofuran (500 ml) was added dropwise with ice water cooling to room temperature. After 2 hours, the mixture was cooled with ice water, and a saturated aqueous sodium hydrogen carbonate solution (100 ml) was added dropwise. Saturated aqueous sodium chloride solution (900 ml) and water (400 ml) were added, followed by extraction with chloroform (1 L × 2). The organic layer was washed with 0.01% aqueous sodium thiosulfate solution (1L) and sodium saturated chloride solution (500 ml), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 127.1 g (quantitative) of the target compound as a yellow oil.
[474] IR (neat): 3292, 2928, 1606, 1558, 1419 cm ^-1
[475] Intermediate Preparation Example 18
[476] 3- (t-butyldiphenylsilyloxy) -3- (4-pyridyl) propylamine (intermediate 18-1)
[477] Diisopropylamine (1.98 g, 19.6 mmol) was added dropwise over 5 minutes to anhydrous tetrahydrofuran (20 ml) solution of butyllithium hexane solution (10,5 ml, 16.8 mmol) at -80 ° C. It heated up and stirred for 30 minutes. After cooling to -80 ° C again, acetonitrile (573 mg, 14.0 mmol) was added dropwise over 7 minutes, and after 20 minutes, 4-pyridinecarboxyaldehyde (758 mg, 7.08 mmol) was added dropwise over 10 minutes. After 50 minutes, saturated aqueous ammonium chloride solution (20 ml) was added to return to room temperature. The reaction solution was extracted continuously (ethyl acetate, water) for 4 days. The organic layer was dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 3-hydroxy-3- (4-pyridyl) propionitrile (666 mg, colorless crystals, 63.5%). Could.
[478] Then imidazole (4.60 g, 67.5 mmol) and N, N-dimethylformamide (30 ml) were added to the obtained 3-hydroxy-3- (4-pyridyl) propionitrile (1.00 g, 6.75 mmol). It stirred at room temperature. t-butyldiphenylchlorosilane (2.23 g, 8.10 mmol) was added, the mixture was stirred overnight, and further stirred at an external temperature of 50 ° C for 3 hours. Ethyl acetate (50 ml) ether (50 ml) was added, washed three times with water (20 ml) and saturated brine (30 mL), and the organic layer was dried over anhydrous magnesium sulfate. After concentration under reduced pressure, the residue was separated and purified by silica gel column chromatography to obtain 2.58 g (98.9%) of 3- (t-butyldiphenylsiloxy) -3- (4-pyridyl) propionitrile as a colorless oil. lost.
[479] 3- (t-butyldiphenylsiloxy) -3- (4-pyridine obtained by suspending lithium aluminum hydride (299 mg, 7.87 mmol) in anhydrous diethyl ether (10 ml) under nitrogen atmosphere and stirring under ice cooling. Anhydrous diethyl ether (15 ml) solution of diyl) propionitrile (1.00 g, 2.59 mmol) was added dropwise over 8 minutes, returned to room temperature and stirred for 75 minutes. Ethyl acetate (15 ml) was added with ice cooling, then water (0.28 ml), 15% aqueous sodium hydroxide solution (0.28 ml), and water (0.85 ml) were added sequentially, and the mixture was returned to room temperature and stirred for 10 minutes. Anhydrous magnesium sulfate was added to the reaction mixture, followed by drying. The solvent was evaporated under reduced pressure to be purified by silica gel column chromatography to obtain the target compound (180.0 mg, yellow oil, 17.8%).
[480] IR (neat): 3286, 3071, 2932, 2858, 1601, 1428 cm ^-1
[481] The following compounds were obtained by the same operation as the intermediate preparation example 18.
[482] 3- (t-butyldimethylsilyloxy) -3- (4-pyridyl) propylamine (intermediate 18-2)
[483] Intermediate Preparation Example 19
[484] N- [2- (1-adamantyl) ethyl] -2-butynylamine (intermediate 19-1)
[485] Dimethyl sulfoxide (60 ml) and triethylamine (8.4 ml, 60 mmol) were added to 2-butyn-1-ol (3.0 ml, 40 mmol), and it stirred under ice-cooling. Sulfur trioxide pyridine complex (4.2 g, 26 mmol) was added 15 minutes later, sulfur trioxide pyridine complex (5.1 g, 32 mmol) was further added, and the mixture was stirred for 1.5 hours. Water (40 ml) was added to the reaction solution, extracted twice with methylene chloride (40 ml), washed twice with 1N hydrochloric acid (30 ml) and water (40 ml) twice, and then the organic layer was dried over anhydrous magnesium sulfate. Dried. The solvent was evaporated off under reduced pressure to yield 1.0 g (37%) of 2-butynal as a brown oil.
[486] Subsequently, 2- (1-adamantyl) ethylamine hydrochloride (2.0 g, 9.3 mmol) was partitioned between chloroform (30 ml) and 1N aqueous sodium hydroxide solution (40 ml), and the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Methanol (15 ml) and triethylamine (2.6 ml, 19 mmol) were added to 2- (1-adamantyl) ethylamine obtained by stirring, and it stirred at room temperature. Next, a methanol (10 ml) solution of 2-butynal (0.80 g, 12 mmol) obtained in the previous reaction was added, and after 3 hours, sodium borohydride (1.9 g, 50 mmol) was added under ice water cooling. After 1 hour, water (40 ml) was added, extracted with chloroform (60 ml), washed with saturated brine (40 ml), and the organic layer was dried over anhydrous magnesium sulfate. After concentration under reduced pressure, the residue was separated and purified by silica gel column chromatography to obtain 0.48 g (22%) of the target compound as a brown oil.
[487] IR (neat): 3302, 2902, 2846, 2279, 2244 cm ^-1
[488] [B] Preparation Example of the Present Compound
[489] This compound preparation example 1
[490] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-1)
[491] 1,1'-carbonyldiimidazole (427 mg, 2,63 mmol) in tetrahydrofuran (10 ml) solution of 4- (3-aminopropyl) pyridine (285 mg, 2.09 mmol) of intermediate 2-1 Was added and stirred at room temperature for 20 minutes. 2- (1-adamantyl) -N-pentylethylamine hydrochloride (571 mg, 2.00 mmol) of Intermediate 1-1 was added and heated to reflux for 1 hour. The mixture was diluted with ethyl acetate (50 ml), washed with saturated aqueous sodium hydrogen carbonate solution (50 ml) and saturated aqueous sodium chloride solution (50 ml), and dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the precipitated solid was washed with diisopropyl ether and filtered off to obtain 606 mg (73%) of the target compound.
[492] IR (KBr): 2900, 2845, 1618, 1534 cm ^-1
[493] mp: 124.0-124.7 ° C.
[494] The following compounds were obtained by the same operation as in the present compound Preparation Example 1.
[495] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea (Compound 1-2)
[496] IR (neat): 3339, 2902, 2846, 1626, 1530 cm ^-1
[497] N- [3- (4-pyridyl) propyl] -1-piperidinecarboxyamide (Compound 1-3)
[498] IR (neat): 3339, 2934, 2854, 1621, 1538 cm ^-1
[499] N- [3- (4-pyridyl) propyl] -1,2,3,6-tetrahydropyridine-1-carboxamide (Compound 1-4)
[500] IR (neat): 3337, 2922, 2858, 1624, 1537, 1414 cm ^-1
[501] N- [3- (4-pyridyl) propyl] -1,2,3,4-tetrahydroisoquinoline-2-carboxamide (Compound 1-5)
[502] IR (KBr): 3342, 2925, 1614, 1543, 1489 cm ^-1
[503] mp: 76.0-79.0 ° C.
[504] N- [3- (4-pyridyl) propyl] -4-morpholinecarboxamide (Compound 1-6)
[505] IR (KBr): 3347, 2968, 1626, 1546, 1115 cm ^-1
[506] mp: 94.0-98.0 ° C.
[507] N- [3- (4-pyridyl) propyl] -1-homopiperidinecarboxamide (Compound 1-7)
[508] IR (neat): 3343, 2927, 1625, 1537 cm ^-1
[509] 1,1-diallyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-8)
[510] IR (neat): 3350, 2928, 1628, 1603, 1535 cm ^-1
[511] N- [3- (4-pyridyl) propyl] -2-decahydroisoquinolinecarboxamide (Compound 1-9)
[512] IR (neat): 3343, 2855, 2622, 1621, 1539 cm ^-1
[513] 1,1-dibutyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-10)
[514] IR (neat): 3347, 2957, 2872, 1626, 1537 cm ^-1
[515] 1,1-dihexyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-11)
[516] IR (neat): 3348, 2928, 2857, 1626, 1532 cm ^-1
[517] 1,1-diisopentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-12)
[518] IR (neat): 3344, 2955, 2869, 1626, 1533 cm ^-1
[519] 1,1-didecyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-13)
[520] IR (neat): 3346, 2925, 2854, 1626, 1537 cm ^-1
[521] 1- [2- (1-adamantyl) ethyl] -1- [2- (N-benzyloxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] Urea (Compound 1-14)
[522] IR (neat): 3360, 2902, 2846, 1772, 1699, 1634, 1532 cm ^-1
[523] 1- [2- (1-adamantyl) ethyl] -1- [2- (dimethylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-15)
[524] IR (KBr): 3322, 2900, 2845, 1621, 1526 cm ^-1
[525] mp: 104.0-106.5 ° C.
[526] 1- [2- (1-adamantyl) ethyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-16)
[527] IR (KBr): 3331, 2901, 2846, 1622, 1602, 1534 cm ^-1
[528] mp: 99.0-103.0 ° C.
[529] 1- [2- (1-adamantyl) ethyl] -1- (2-propynyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-17)
[530] IR (KBr): 3322, 3204, 2899, 2845, 2112, 1626, 1605, 1543, 1444 cm ^-1
[531] mp: 152.0-154.0 ° C
[532] 1- [2- (1-adamantyl) ethyl] -1- (2-methoxyethyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-18)
[533] IR (KBr): 3321, 2900, 2846, 1625, 1602, 1534, 1451 cm ^-1
[534] mp: 101.5-104.5 ° C.
[535] 1- [2- (1-adamantyl) ethyl] -1-cyclopropyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-19)
[536] IR (KBr): 3365, 2900, 1633 cm ^-1
[537] mp: 108.0-115.5 ° C.
[538] 1- [2- (1-adamantyl) ethyl] -1-cyanomethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-20)
[539] IR (neat): 3350, 2903, 2247, 1644 cm ^-1
[540] 1- [2- (1-adamantyl) ethyl] -1-cyclopentylmethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-21)
[541] IR (KBr): 3328, 2906, 2845, 1615, 1450 cm ^-1
[542] mp: 155.0-158.0 ° C.
[543] 1- [2- (1-adamantyl) ethyl] -1-cyclopropylmethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-22)
[544] IR (KBr): 3328, 2900, 2845, 1618, 1534 cm ^-1
[545] mp: 123.0-125.0 ° C.
[546] 1- [2- (1-adamantyl) ethyl] -1-allyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-23)
[547] IR (KBr): 3329, 2900, 1625, 1538 cm ^-1
[548] mp: 99.0-102.0 ° C
[549] 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea (Compound 1-24) )
[550] IR (KBr): 3310, 2900, 2847, 1622, 1543 cm ^-1
[551] mp: 107.5-109.0 ° C.
[552] 1- [2- (1-adamantyl) ethyl] -1- (2-butenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-25)
[553] IR (KBr): 3328, 2900, 1619 cm ^-1
[554] mp: 89.5-93.5 ° C.
[555] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyri Dill) propyl] urea (compound 1-26)
[556] IR (neat): 3350, 2903, 2846, 1694, 1633, 1537 cm ^-1
[557] 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (2-thienyl) methylurea (Compound 1-27)
[558] IR (KBr): 3328, 2900, 2845, 1626, 1544 cm ^-1
[559] mp: 142.5-144.5 ° C.
[560] 1- [2- (1-adamantyl) ethyl] -1-benzyloxy-3- [3- (4-pyridyl) propyl] urea (Compound 1-28)
[561] IR (neat): 3444, 3350, 2902, 2846, 1666, 1517 cm ^-1
[562] 1- [2- (1-adamantyl) ethyl] -1-hexyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-29)
[563] IR (KBr): 3354, 2901, 2845, 1619, 1538 cm ^-1
[564] mp: 119.5-121.5 ° C.
[565] 1- (1-adamantyl) methyl-1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-30)
[566] IR (neat): 3350, 2902, 1626 cm ^-1
[567] 1- [2- (1-adamantyl) ethyl] -1- (3-methyl-2-butenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-31)
[568] IR (KBr): 3358, 2900, 2845, 1622, 1526 cm ^-1
[569] mp: 93.0-96.0 ° C.
[570] 1- [2- (1-adamantyl) ethyl] -1-decyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-32)
[571] IR (KBr): 3340, 2924, 2846, 1626, 1602, 1534 cm ^-1
[572] mp: 75,0-76.0 ° C
[573] 1- [2- (1-adamantyl) ethyl] -1- (2-methyl-2-propenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-33)
[574] IR (KBr): 3336, 2905, 2846, 1624, 1544 cm ^-1
[575] mp: 108.0-109.0 ° C.
[576] 1- [2- (1-adamantyl) ethyl] -1-cinnamil-3- [3- (4-pyridyl) propyl] urea (Compound 1-34)
[577] IR (KBr): 3374, 2899, 2844, 1619, 1534 cm ^-1
[578] mp: 130.0-134.5 ° C.
[579] 1- [3- (1-adamantyl) propyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-35)
[580] IR (neat): 3349, 2901, 1626, 1536 cm ^-1
[581] 1- (1-adamantyl) methyl-1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-36)
[582] IR (neat): 3349, 2903, 1625, 1531 cm ^-1
[583] 1- [2- (1-adamantyl) ethyl] -1- (2-methylthiazol-4-yl) methyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-37 )
[584] IR (neat): 3337, 2901, 1632, 1536 cm ^-1
[585] 1,1-dipentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-38)
[586] IR (neat): 3347, 2929, 2859, 1626, 1537 cm ^-1
[587] 1-pentyl-1- (2-piperidinoethyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-39)
[588] IR (neat): 3350, 2933, 2856, 1640, 1533 cm ^-1
[589] 1- [2- (1-adamantyl) ethyl] -1-methyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-40)
[590] IR (KBr): 3334, 2901, 2846, 1626, 1604, 1534 cm ^-1
[591] mp: 99.0-109.0 ° C.
[592] 1- [2- (1-adamantyl) ethyl] -1-ethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-41)
[593] IR (KBr): 3324, 2901, 2845, 1622, 1540 cm ^-1
[594] mp: 106.0-115.0 ° C.
[595] 1- [2- (1-adamantyl) ethyl] -1-furfuryl-3- [3- (4-pyridyl) propyl] urea (Compound 1-42)
[596] IR (KBr): 3331, 2900, 2846, 1618, 1538 cm ^-1
[597] mp: 128.0-130.0 ° C
[598] 1- [2- (1-adamantyl) ethyl] -1-benzyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-43)
[599] IR (KBr): 3335, 2901, 2847, 1619, 1538 cm ^-1
[600] mp: 130.5-135.0 ° C
[601] 1- (2-cyclohexylethyl) -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-44)
[602] IR (neat): 3345, 2923, 1625, 1603, 1531 cm ^-1
[603] 1-pentyl-1-phenethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-45)
[604] IR (neat): 3345, 3063, 2929, 1625, 1533 cm ^-1
[605] 1-butyl-1- (2-cyclohexylethyl) -3- (4-pyridyl) methylurea (Compound 1-46)
[606] IR (neat): 3342, 2922, 2851, 1629, 1602, 1563, 1530, 1448 cm ^-1
[607] 1- (2-cyclohexylethyl) -1,3-bis [(4-pyridyl) methyl] urea (Compound 1-47)
[608] IR (neat): 3337, 3029, 2922, 2850, 1633, 1602, 1534, 1445 cm ^-1
[609] 1- (2-cyclohexylethyl) -3- (4-pyridyl) methyl-1- (2-thienyl) methylurea (Compound 1-48)
[610] IR (neat): 3342, 2921, 2850, 1631, 1602, 1562, 1536, 1415, 1267, 1227 cm ^-1
[611] 1- [2- (t-butoxycarbonyl) ethyl] -1- (2-cyclohexylethyl) -3- (4-pyridyl) methylurea (Compound 1-49)
[612] IR (neat): 3347, 2977, 2923, 2851, 1727, 1633, 1602, 1563, 1531, 1449 cm ^-1
[613] 1- (2-cyclohexylethyl) -1- [2- (methoxycarbonyl) ethyl] -3- (4-pyridyl) methylurea (compound 1-50)
[614] IR (neat): 3348, 2923, 2850, 1737, 1633, 1603, 1563, 1532, 1437 cm ^-1
[615] 1- (2-carbamoylethyl) -1- (2-cyclohexylethyl) -3- (4-pyridyl) methylurea (Compound 1-51)
[616] IR (neat): 3324, 2922, 2850, 1673, 1632, 1606, 1563, 1530, 1448 cm ^-1
[617] 1- (2-cyclohexylethyl) -1-pentyl-3- (4-pyridyl) methylurea (compound 1-52)
[618] IR (KBr): 3313, 2925, 1627, 1602, 1527, 1410 cm ^-1
[619] mp: 64.7-65.8 ° C.
[620] 1- (2-cyclohexylethyl) -1- (2-dimethylaminoethyl) -3- (4-pyridyl) methylurea (compound 1-53)
[621] IR (KBr): 3346, 2922, 2850, 2778, 1635, 1562, 1533, 1448 cm ^-1
[622] 1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -1- (2-cyclohexylethyl) -3- (4-pyridyl) methylurea (Compound 1- 54)
[623] IR (neat): 3338, 2976, 2924, 2851, 1694, 1633, 1602, 1563, 1531, 1484, 1450 cm ^-1
[624] 1-pentyl-1- [2- (2-pyridyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-55)
[625] IR (neat): 3350, 2929, 2859, 1633, 1602, 1537 cm ^-1
[626] 1,1-bis [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-56)
[627] IR (neat): 3358, 2901, 2845, 1625, 1530 cm ^-1
[628] mp: 80 ° C.
[629] 1- [2- (1-adamantyl) ethyl] -1-butyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-57)
[630] IR (KBr): 3315, 2901, 1618, 1534 cm ^-1
[631] mp: 109.5-118.0 ° C.
[632] 1,1-bis (2-hydroxypropyl) -3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 1-58)
[633] IR (neat): 3350, 1688, 1638, 1538 cm ^-1
[634] 1- [bis (t-butoxycarbonylaminomethyl)] methyl-1-isopentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-59)
[635] IR (neat): 3326, 2960, 1698, 1631, 1525 cm ^-1
[636] 1-cyclohexyl (phenyl) methyl-1- (3-phenylpropyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-60)
[637] IR (KBr): 3352, 2931, 1619, 1522 cm ^-1
[638] mp: 107.0-112.0 ° C
[639] 1,1-dicyclohexyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-61)
[640] IR (KBr): 3304, 2930, 2848, 1638, 1602, 1533 cm ^-1
[641] mp: 143.0-145.5 ° C.
[642] 1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -1-phenethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-62 )
[643] IR (neat): 3350, 1694, 1633, 1532, 1166 cm ^-1
[644] 1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-63)
[645] IR (neat): 3350, 1694, 1632, 1537, 1167 cm ^-1
[646] 1- [2- (N-benzyloxycarbonyl-N-methylamino) ethyl] -1-phenethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-64)
[647] IR (neat): 3350, 1698, 1632, 1531 cm ^-1
[648] 1- [3- (1-adamantyl) propyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-65)
[649] IR (KBr): 3333, 2901, 2844, 1623, 1602, 1543 cm ^-1
[650] 1- [2- (1-adamantyl) ethyl] -3-pentyl-1- [3- (4-pyridyl) propyl] urea (Compound 1-66)
[651] IR (KBr): 3370, 3322, 2903, 2846, 1618, 1534 cm ^-1
[652] mp: 47.0-50.0 ° C.
[653] 3- [2- (1-adamantyl) ethyl] -1- [2- (t-butoxycarbonyl) ethyl] -1- [3- (4-pyridyl) propyl] urea (Compound 1- 67)
[654] IR (neat): 3348, 2902, 2846, 1726, 1627, 1538, 1367, 1152 cm ^-1
[655] 1- [2- (1-adamantyl) ethyl] -1-isopropyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-68)
[656] IR (KBr): 3330, 2903, 2845, 1614, 1533 cm ^-1
[657] mp: 132.0-134.0 ° C
[658] 1- [2- (1-adamantyl) ethyl] -1- [2- (t-butoxycarbonyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1- 69)
[659] IR (KBr): 3356, 2903, 1720, 1622, 1538, 1156 cm ^-1
[660] mp: 124.5-127.0 ° C.
[661] 1- [2- (1-adamantyl) ethyl] -1-cyclopentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-70)
[662] IR (KBr): 3297, 2906, 2844, 1618, 1544 cm ^-1
[663] mp: 135.5-137.5 ° C.
[664] 1- [2- (1-adamantyl) ethyl] -1- (t-butoxycarbonylamino) -3- [3- (4-pyridyl) propyl] urea (Compound 1-71)
[665] IR (neat): 3231, 2903, 1732, 1650 cm ^-1
[666] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- (2-pyridyl) methylurea (Compound 1-72)
[667] IR (KBr): 3333, 2900, 2844, 1625, 1535 cm ^-1
[668] mp: 87.5-92.0 ° C
[669] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- (3-pyridyl) methylurea (Compound 1-73)
[670] IR (KBr): 3328, 2901, 2846, 1622, 1530 cm ^-1
[671] mp: 88.5-101.5 ° C.
[672] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- (4-pyridyl) methylurea (Compound 1-74)
[673] IR (KBr): 3331, 2900, 2845, 1626, 1538 cm ^-1
[674] mp: 96.5-108.0 ° C
[675] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (2-pyridyl) ethyl] urea (Compound 1-75)
[676] IR (KBr): 3346, 2904, 2845, 1622, 1539 cm ^-1
[677] mp: 80.0-100.0 ° C
[678] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (3-pyridyl) ethyl] urea (Compound 1-76)
[679] IR (KBr): 3334, 2900, 2845, 1618, 1541 cm ^-1
[680] mp: 112.5-114.5 ° C.
[681] 1- (2-cyclohexylethyl) -1- (2-methoxyethyl) -3- (4-pyridyl) methylurea (Compound 1-77)
[682] IR (neat): 3350, 2922, 2850, 1633, 1603, 1534 cm ^-1
[683] 1- [2- (N-benzyloxycarbonyl-N-methylamino) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-78)
[684] IR (neat): 3358, 2930, 1701, 1633, 1534 cm ^-1
[685] 1-ethyl-3- [3- (4-pyridyl) propyl] -1- (3,4,5-trimethoxyphenethyl) urea (Compound 1-79)
[686] IR (neat): 3350, 2936, 1626, 1590, 1530, 1239 cm ^-1
[687] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridyl) ethyl] urea (Compound 1-80)
[688] IR (KBr): 3346, 2901, 2844, 1622, 1538 cm ^-1
[689] mp: 107-118 ° C.
[690] 1- [2- (1H-5-imidazolyl) ethyl] -1-isopentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-81)
[691] IR (neat): 3117, 2954, 1606, 1537 cm ^-1
[692] 1-cyclohexyl-1- (3,4-dimethoxyphenethyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-82)
[693] IR (neat): 3353, 2931, 1621, 1515, 1236, 1029 cm ^-1
[694] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (2-pyridyl) propyl] urea (Compound 1-83)
[695] IR (KBr): 3324, 2900, 2845, 1622, 1538 cm ^-1
[696] mp: 84.4-85.7 ° C.
[697] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (3-pyridyl) propyl] urea (Compound 1-84)
[698] IR (KBr): 3355, 2902, 2845, 1615, 1526 cm ^-1
[699] mp: 99.9-105.2 ° C.
[700] 1-cyclopropyl-3- [3- (4-pyridyl) propyl] -1- (3,4,5-trimethoxyphenethyl) urea (Compound 1-85)
[701] IR (neat): 3400, 2938, 1644, 1590, 1510, 1239, 1128 cm ^-1
[702] 1- [2- (1-adamantyl) ethyl] -3- (4-dimethylamino) phenethyl-1-pentylurea (Compound 1-86)
[703] IR (KBr): 3341, 2900, 2845, 1619, 1526 cm ^-1
[704] mp: 115.8-118.1 ° C.
[705] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [4- (4-pyridyl) butyl] urea (Compound 1-87)
[706] IR (KBr): 3354, 2900, 2844, 1618, 1538 cm ^-1
[707] mp: 74.1-78.1 ° C.
[708] 1- [2- (1-adamantyl) ethyl] -3- (t-butoxycarbonyl) -1-pentyl-3- [2- (4-pyridyl) oxyethyl] urea (Compound 1- 88)
[709] IR (neat): 2903, 2847, 1704, 1590 cm ^-1
[710] 1- [2- (1-adamantyl) ethyl] -1- [3- [N- (t-butoxycarbonyl) -N-methylamino] propyl] -3- [3- (4-pyri Dill) propyl] urea (compound 1-89)
[711] IR (neat): 3350, 2903, 2847, 1694, 1632, 1531 cm ^-1
[712] 1-cyclohexyl (phenyl) methyl-1- [3- (4-methoxyphenoxy) propyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-90)
[713] IR (neat): 3369, 2930, 1626, 1510, 1231 cm ^-1
[714] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-quinolyl) propyl] urea (Compound 1-91)
[715] IR (KBr): 3354, 2902, 2845, 1622, 1534 cm ^-1
[716] mp: 80.2-102.0 ° C
[717] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (1-imidazolylcarbonyl) -N-methylamino] ethyl] -3- [3- (4- Pyridyl) propyl] urea (Compound 1-92)
[718] IR (neat): 3366, 2902, 2846, 1695, 1635, 1604, 1531 cm ^-1
[719] 1-diphenylmethyl-1- (3-phenylpropyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-93)
[720] IR (KBr): 3334, 3026, 2927, 1621, 1522 cm ^-1
[721] mp: 123.0-124.8 ° C
[722] 1,1-di- (5-hexenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-94)
[723] IR (neat): 3350, 3074, 2930, 2859, 1621, 1538 cm ^-1
[724] 1,1-di- (7-octenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-95)
[725] IR (neat): 3349, 3074, 2927, 2856, 1625, 1537 cm ^-1
[726] 4- [2- [3- [2- (1-adamantyl) ethyl] -3-pentyl] ureidoethyl] benzenesulfonamide (compound 1-96)
[727] IR (KBr): 3423, 2906, 2847, 1598, 1540, 1161 cm ^-1
[728] mp: 85.0-120.7 ° C.
[729] 1- [2- (1-adamantyl) ethyl] -3- (1-imidazolyl) propyl-1-pentylurea (Compound 1-97)
[730] IR (KBr): 3340, 2902, 2845, 1618, 1534 cm ^-1
[731] mp: 97.0-100.0 ° C
[732] 1- [2- (1-adamantyl) ethyl] -3- (4-hydroxyphenethyl) -1-pentylurea (Compound 1-98)
[733] IR (KBr): 3392, 2902, 2845, 1614, 1535, 1515 cm ^-1
[734] mp: 96.3-99.4 ° C.
[735] 1- [2- (1-adamantyl) ethyl] -1- [2- (3-t-butyl-1-methylureido) ethyl] -3- [3- (4-pyridyl) propyl] Urea (Compound 1-99)
[736] IR (neat): 3310, 2903, 1632, 1537 cm ^-1
[737] 1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-100)
[738] IR (KBr): 3347, 2957, 2902, 2846, 1621, 1604, 1539 cm ^-1
[739] mp: 105.3-112.3 ° C.
[740] 1- [2- (1-adamantyl) ethyl] -1- [2- (1-methyl-3-propylureido) ethyl] -3- [3- (4-pyridyl) propyl] urea ( Compound 1-101)
[741] IR (neat): 3316, 2902, 1631, 1537 cm ^-1
[742] 1-pentyl-1- (3-phenylpropyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-102)
[743] IR (neat): 3348, 2929, 1625, 1537 cm ^-1
[744] 1- [2- (acetylamino) ethyl] -1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-103)
[745] IR (neat): 3291, 2902, 2846, 1632, 1556, 753 cm ^-1
[746] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) butyl] urea (Compound 1-104)
[747] IR (KBr): 3346, 2901, 2845, 1618, 1601, 1539 cm ^-1
[748] mp: 93.0-98.0 ° C
[749] 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (4,4,4-trifluorobutyl) urea (compound 1-105) )
[750] IR (KBr): 3317, 2901, 2846, 1618, 1538, 1255, 1123 cm ^-1
[751] mp: 142.6-145.0 ° C.
[752] 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (5,5,5-trifluoropentyl) urea (Compound 1-106) )
[753] IR (KBr): 3333, 200, 2846, 1618, 1534, 1259, 1140 cm ^-1
[754] mp: 116.9-118.9 ° C.
[755] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] urea (Compound 1-107)
[756] IR (neat): 3350, 2902, 2846, 1694, 1672, 1633, 1603, 1537 cm ^-1
[757] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridylmethyl) butyl] urea (Compound 1-108)
[758] IR (KBr): 3347, 2900, 2845, 1622, 1538 cm ^-1
[759] mp: 72.0-77.0 ° C
[760] 1- [2- (1-adamantyl) ethyl] -3- [2-benzyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-109)
[761] IR (KBr): 3329, 2902, 2846, 1622, 1544 cm ^-1
[762] mp: 111.0-116.0 ° C.
[763] 1- [2- (1-adamantyl) ethyl] -3- [2,2-bis (4-pyridylmethyl) ethyl] -1-pentylurea (Compound 1-110)
[764] IR (KBr): 3330, 2905, 2845, 1619, 1602, 1534 cm ^-1
[765] mp: 124.0-136.0 ° C.
[766] (Z) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea (Compound 1-111)
[767] IR (neat): 3338, 2901, 2846, 1625, 1596, 1530 cm ^-1
[768] (E) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea (Compound 1-112)
[769] IR (KBr): 3315, 2900, 2845, 1623, 1526 cm ^-1
[770] mp: 90-118 ° C.
[771] 1-isopentyl-3- [3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea (Compound 1-113)
[772] IR (neat): 3342, 2956, 1628, 1604, 1539 cm ^-1
[773] 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (2,2,2-trifluoroethyl) urea (Compound 1-114) )
[774] IR (KBr): 3346, 2901, 2847, 1630, 1604, 1544, 1145, 1108 cm ^-1
[775] mp: 106.2-107.3 ° C.
[776] 3- [2-methyl-3- (4-pyridyl) propyl] -1-pentyl-1-phenethylurea (Compound 1-115)
[777] IR (KBr): 3352, 2927, 2858, 1622, 1530, 1496, 1453, 1416, 1276 cm ^-1
[778] mp: 49.0-50.0 ° C.
[779] 1,1-dibutyl-3- [2-methyl-3- (4-pyridyl) propyl] urea (Compound 1-116)
[780] IR (neat): 3347, 2957, 2929, 1624, 1534 cm ^-1
[781] 1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea ( Compound 1-117)
[782] IR (KBr): 3354, 2901, 2847, 1626, 1540 cm ^-1
[783] mp: 81.1-84.1 ° C.
[784] 1- (2-cyclohexylethyl) -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea (compound 1-118)
[785] IR (neat): 3346, 2923, 2852, 1625, 1533 cm ^-1
[786] 1- (3-cyclohexylpropyl) -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-119)
[787] IR (neat): 3346, 2922, 1626, 1537 cm ^-1
[788] (-)-1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-120)
[789] IR (KBr): 3337, 2900, 1616, 1526 cm ^-1
[790] mp: 103.0-104.0 ° C.
[791] [α] ²⁰ _D : -4.6 ° (MeOH, C1.0)
[792] (+)-1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-121)
[793] IR (KBr): 3336, 2900, 1616, 1526 cm ^-1
[794] mp: 102.9-103.5 ° C.
[795] [α] ²⁰ _D : + 4.2 ° (MeOH, C1.0)
[796] 1- [3- (1-adamantyl) propyl] -1-butyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-122)
[797] IR (KBr): 3323, 2954, 2904, 2846, 1624, 1603, 1548 cm ^-1
[798] mp: 79.8-80.4 ° C.
[799] 1- [3- (1-adamantyl) propyl] -3- [3- (4-pyridyl) propyl] -1- (2,2,2-trifluoroethyl) urea (Compound 1-123 )
[800] IR (KBr): 3355, 2902, 2848, 1627, 1605, 1545, 1145, 1112 cm ^-1
[801] mp: 88.9-90.0 ° C
[802] 1- [4- (1-adamantyl) butyl] -1-ethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-124)
[803] IR (KBr): 3352, 2897, 2847, 1626, 1604, 1539 cm ^-1
[804] mp: 92.7-93.7 ° C
[805] 1- [4- (1-adamantyl) butyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-125)
[806] IR (KBr): 3343, 2900, 2847, 1625, 1604, 1544 cm ^-1
[807] mp: 110.0-110.5 ° C.
[808] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridylamino) ethyl] urea (Compound 1-126)
[809] IR (KBr): 3301, 2904, 2848, 1628, 1602, 1527 cm ^-1
[810] mp: 133.9-134.5 ° C.
[811] (+)-1- [3- (1-adamantyl) propyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-propylurea (Compound 1-127)
[812] IR (neat): 3350, 2902, 2846, 1625, 1534 cm ^-1
[813] [α] ²⁰ _D : + 4.2 ° (MeOH, C0.51)
[814] 1- [3- (1-adamantyl) propyl] -1-propyl-3- (4-pyridyl) methylurea (Compound 1-128)
[815] IR (KBr): 3319, 2902, 1630, 1604, 1537 cm ^-1
[816] mp: 96.0-98.0 ℃
[817] 1- [3- (1-adamantyl) propyl] -1-propyl-3- [2- (4-pyridyl) ethyl] urea (Compound 1-129)
[818] IR (neat): 3345, 2901, 1634, 1538 cm ^-1
[819] 1- [3- (1-adamantyl) propyl] -1-ethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-130)
[820] IR (KBr): 3345, 2969, 2905, 2845, 1622, 1605, 1535 cm ^-1
[821] mp: 97,5-98.2 ° C.
[822] 1- [2- (1-adamantyloxy) ethyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-131)
[823] IR (neat): 3344, 2911, 2853, 1642, 1603, 1534 cm ^-1
[824] 1- (1-adamantyl) aminocarbonylmethyl-1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-132)
[825] IR (KBr): 3335, 3261, 2910, 2853, 1662, 1622, 1543 cm ^-1
[826] mp: 132.0-132.5 ° C
[827] 1- [3- (1-adamantyl) propyl] -1-propyl-3- [4- (4-pyridyl) butyl] urea (Compound 1-133)
[828] IR (neat): 3350, 2901, 1623, 1532 cm ^-1
[829] 1- [3- (1-adamantyl) propyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyri Dill) propyl] urea (compound 1-134)
[830] IR (neat): 3347, 2902, 2846, 1696, 1632, 1603, 1534, 1167 cm ^-1
[831] 1- [2- (1-adamantyl) ethyl] -3- [2,2-dimethyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-135)
[832] IR (KBr): 3338, 2905, 1620. 1600, 1541 cm ^-1
[833] mp: 82.5-84.9 ° C
[834] 1- [3- (1-adamantyl) propyl] -3- [3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea (compound 1-136 )
[835] IR (neat): 3349, 2902, 1628, 1538 cm ^-1
[836] 1- [2- (1-adamantyl) ethyl] -3- [1-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-137)
[837] IR (KBr): 3338, 2902, 2847, 1615, 1533 cm ^-1
[838] mp: 128.5-129.0 ° C
[839] 1- [2- (1-adamantyl) ethyl] -3- [3- (t-butyldimethylsilyloxy) -3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-138 )
[840] IR (neat): 3355, 2904, 2849, 1628, 1600, 1532, 1099 cm ^-1
[841] (+)-1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [2- Methyl-3- (4-pyridyl) propyl] urea (Compound 1-139)
[842] IR (KBr): 3345, 2910, 2848, 1693, 1622, 1602, 1538, 1248 cm ^-1
[843] mp: 122.7-123.7 ° C
[844] [α] ²⁰ _D : + 2.8 ° (MeOH, C1.0)
[845] 1- [2- (1-adamantyl) aminoethyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-140)
[846] IR (neat): 3275, 2908, 2849, 1636, 1536 cm ^-1
[847] 1- [2- (1-adamantyl) ethyl] -1- (2-butynyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-141)
[848] IR (neat): 3351, 2903, 2847, 2290, 2221, 1630, 1605, 1538 cm ^-1
[849] 1- [2- (1-adamantyl) ethyl] -3- [1,2-dimethyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-142)
[850] IR (neat): 3354, 2904, 2847, 1623, 1604, 1525 cm ^-1
[851] 1- [2- (1-adamantyl) ethyl] -3- [1-ethyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-143)
[852] IR (neat): 3352, 2904, 2847, 1622, 1605, 1529 cm ^-1
[853] 1- [2- (1-adamantyl) ethyl] -3- [3- (t-butyldiphenylsilyloxy) -3- (4-pyridyl) propyl] -1-pentylurea (compound 1- 144)
[854] IR (neat): 3360, 3072, 3050, 2903, 2849, 1634, 1602, 1532, 1428 cm ^-1
[855] This compound preparation example 2
[856] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N-propylamide (Compound 2-1)
[857] 2- (1-adamantyl) -N-propylethylamine (0.37 g, 1.7 mmol) of intermediate 1-6, 5- (4-pyridyl) valeric acid (0.30 g, 1,7) in intermediate 5-1 N, N-dimethylformamide (8.4 ml) was added to mmol), and the mixture was stirred at room temperature. N-methylmorpholine (0.27 ml, 2.5 mmol), and then 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (0.38 g, 2.0 mmol) were added and stirred overnight. The reaction solution was concentrated under reduced pressure, ethyl acetate (20 ml) was added to the residue, followed by washing with saturated sodium bicarbonate (20 ml) and saturated brine (5 ml). After drying over sodium sulfate, ethyl acetate was evaporated off under reduced pressure. The residue was purified by basic silica gel column chromatography to give 0.21 g (33%) of the target compound as a colorless oil.
[858] IR (neat): 2092, 2846, 1644, 1602 cm ^-1
[859] The following compounds were obtained by the same operation as in the present compound Preparation Example 2.
[860] 5- (4-pyridyl) valeric acid N- (1-adamantyl) methyl-N-propylamide (Compound 2-2)
[861] IR (neat): 3067, 2903, 2847, 1644, 1602 cm ^-1
[862] 5- (4-pyridyl) valeric acid N- (1-adamantyl) methyl-N-pentylamide (Compound 2-3)
[863] IR (neat): 2903, 2847, 1644, 1601, 1454 cm ^-1
[864] 5- (4-pyridyl) valeric acid N, N-dibutylamide (Compound 2-4)
[865] IR (neat): 2958, 2932, 1641, 1602 cm ^-1
[866] 5- (4-pyridyl) valeric acid N, N-diisopentylamide (Compound 2-5)
[867] IR (neat): 2956, 2870, 1639, 1603 cm ^-1
[868] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- (2-butenyl) amide (Compound 2-6)
[869] IR (neat): 2903, 2847, 1642, 1602 cm ^-1
[870] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- [2- [N '-(t-butoxycarbonyl) -N'-methylamino] Ethyl] amide (Compound 2-7)
[871] IR (neat): 2904, 2847, 1695, 1644, 1602 cm ^-1
[872] 5- (4-pyridyl) valeric acid N- [3- (1-adamantyl) propyl] -N-propylamide (Compound 2-8)
[873] IR (neat): 2902, 2846, 1643, 1602 cm ^-1
[874] 5- (4-pyridyl) valeric acid N-pentyl-N-phenethylamide (Compound 2-9)
[875] IR (neat): 2930, 2860, 1642, 1602 cm ^-1
[876] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- (2-dimethylaminoethyl) amide (Compound 2-10)
[877] IR (neat): 2903, 2847, 1639, 1605 cm ^-1
[878] 5- (4-pyridyl) valeric acid N- (2-cyclohexylethyl) -N-pentylamide (Compound 2-11)
[879] IR (neat): 2924, 2853, 1644, 1601 cm ^-1
[880] 5- (4-pyridyl) valeric acid N, N-bis [2- (1-adamantyl) ethyl] amide (Compound 2-12)
[881] IR (neat): 2901, 2846, 1643, 1602 cm ^-1
[882] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl]-(3,3,3-trifluoropropyl) amide (Compound 2-13)
[883] IR (neat): 2904, 2848, 1647, 1602 cm ^-1
[884] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-14)
[885] IR (neat): 2903, 2847, 1736, 1643, 1602 cm ^-1
[886] 3- (4-Pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-15)
[887] IR (neat): 2903, 1643, 1599 cm ^-1
[888] 2-Methyl-3- (4-pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-16)
[889] IR (neat): 2903, 1639, 1600 cm ^-1
[890] 2- (t-butoxycarbonyl) amino-3- (4-pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-17)
[891] IR (neat): 3284, 2903, 1705, 1644 cm ^-1
[892] 2- [2- (4-pyridyl) ethylthio] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-18)
[893] IR (neat): 2902, 1635, 1602 cm ^-1
[894] (2R) -2- (t-butoxycarbonyl) amino-3- [2- (4-pyridyl) ethylthio] propionic acid N- [2- (1-adamantyl) ethyl] -N-pentyl Amide (Compound 2-19)
[895] IR (neat): 3287, 2903, 1705, 1644, 1602 cm ^-1
[896] [α] ²⁰ _D : -19.0 ° (MeOH, C0.43)
[897] 6- (4-pyridyl) capronic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-20)
[898] IR (neat): 2903, 1644, 1602 cm ^-1
[899] 4- (4-pyridyl) butyric acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-21)
[900] IR (neat): 2903, 1644, 1602 cm ^-1
[901] This compound preparation example 3
[902] 1- [2- (1-adamantyl) ethyl] -1- (2-methylaminoethyl) -3- [3- (4-pyridyl) propyl] urea dihydrochloride (Compound 3-1)
[903] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [3- of compound 1-26 Methanol (4.4 ml) was added to (4-pyridyl) propyl] urea (0.30 g, 0.60 mmol), the calcium chloride tube was attached, and it stirred at room temperature. A 10% hydrogen chloride methanol solution (4.4 ml) was added, and the mixture was stirred under reduced pressure overnight, whereupon 0.30 g (quantitative) of the target compound was obtained as a pale yellow amorphous powder.
[904] IR (neat): 3351, 2904, 2846, 1634, 1538 cm ^-1
[905] The following compounds were obtained by the same operation as in the present compound Preparation Example 3.
[906] 1- (2-cyclohexylethyl) -1- (2-methylaminoethyl) -3- (4-pyridyl) methylurea dihydrochloride (Compound 3-2)
[907] IR (neat): 3323, 2923, 2850, 1638, 1529, 1449 cm ^-1
[908] 1- [2- (1-adamantyl) ethyl] -1-amino-3- [3- (4-pyridyl) propyl] urea dihydrochloride (Compound 3-3)
[909] IR (KBr): 3410, 2902, 1637 cm ^-1
[910] mp: approx. 100 ° C.
[911] 2-Amino-3- (4-pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide dihydrochloride (Compound 3-4)
[912] IR (neat): 3402, 2901, 1638, 1608, 1503 cm ^-1
[913] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- (2-methylaminoethyl) amide (Compound 3-5)
[914] IR (neat): 3312, 2902, 2846, 1643, 1602, 1450, 1416 cm ^-1
[915] (2R) -2-Amino-3- [2- (4-pyridyl) ethylthio] propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide dihydrochloride (Compound 3-6 )
[916] IR (KBr): 3423, 2902, 1638, 1609 cm ^-1
[917] [α] ²⁰ _D : -4.9 ° (H ₂ O, C0.52)
[918] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridyl) oxyethyl] urea (Compound 3-7)
[919] IR (neat): 3246, 2903, 2846, 1698, 1604 cm ^-1
[920] This compound preparation example 4
[921] 4- [3- [3- [2- (1-adamantyl) ethyl] -3-pentylureido] propyl] -1-methylpyridinium iodine salt (Compound 4-1)
[922] Acetone of 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (0.30 g, 0.73 mmol) of compound 1-1 at room temperature Methyl iodide (90 µl, 1.5 mmol) was added to the (1.5 ml) solution, and the mixture was stirred overnight. After the reaction solution was evaporated off under reduced pressure, the crystals precipitated with ethyl acetate were filtered out to obtain 389 mg (96%) of the target compound.
[923] IR (KBr): 3374, 2926, 2900, 1616, 1526 cm ^-1
[924] mp: 168.0-171.0 ° C.
[925] The following compounds were obtained by the same operation as in the present compound Preparation Example 4.
[926] 4- [3- [3- [2- (1-adamantyl) ethyl] -3- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] ureido] propyl ] -1-methylpyridinium iodine salt (Compound 4-2)
[927] IR (neat): 3342, 2903, 2846, 1682, 1644, 1520, 1235, 1166 cm ^-1
[928] 4- [3- [3- [2- (1-adamantyl) ethyl] -3- [2- [N- (t-butoxycarbonyl) amino] ethyl] ureido] propyl] -1- Benzylpyridinium bromine salt (Compound 4-3)
[929] IR (KBr): 3312, 2907, 2846, 1714, 1694, 1625, 1534, 1246, 1171 cm ^-1
[930] mp: 97 ° C.
[931] This compound preparation example 5
[932] N- [2- (1-adamantyl) ethyl] -N-pentylcarbamic acid 3- (4-pyridyl) propyl ester (Compound 5-1)
[933] At room temperature, 4-pyridinepropanol (528 mg, 3.85 mmol) was dissolved in acetonitrile (20 ml), and triethylamine (1.61 ml, 11.6 mmol) was then added. Further, N, N'-disuccinamimidyl ester (1.48 g, 5.87 mmol) was added thereto and stirred for 2.5 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate (100 ml) and saturated aqueous sodium hydrogen carbonate solution (50 ml) were added to the residue, followed by separation. The obtained organic layer was washed with a saturated aqueous sodium chloride solution (50 ml). It dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was dried under reduced pressure and dissolved in anhydrous methylene chloride (10 ml). Next, a solution of methylene chloride (90 ml) of 2- (1-adamantyl) -N-pentylethylamine hydrochloride (1.32 g, 4.62 mmol) and triethylamine (0.80 ml, 5.7 mmol) of intermediate 1-1 was added. It was added and stirred for 1.5 hours. The reaction mixture was washed sequentially with saturated aqueous sodium hydrogen carbonate solution (50 ml) and saturated aqueous sodium chloride solution (50 ml), and dried over anhydrous sodium sulfate. The solvent was evaporated off under reduced pressure, and the residue was purified by silica gel column chromatography to give 1.54 g (97%) of the target compound as an oil.
[934] IR (neat): 2903, 2847, 1742, 1698 cm ^-1
[935] The following compounds were obtained by the same operation as in the present compound Preparation Example 5.
[936] 1- [2- (1-adamantyl) ethyl] -1- [2- (N-cyclohexyloxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) Propyl] urea (Compound 5-2)
[937] IR (neat): 3350, 2904, 2847, 1682, 1633, 1604, 1531 cm ^-1
[938] N- [3- (1-adamantyl) propyl] -N-propylcarbamic acid 3- (4-pyridyl) propyl ester (Compound 5-3)
[939] IR (neat): 2901, 2846, 1740, 1695, 1645, 1602, 1451, 1423 cm ^-1
[940] N- [2- (1-adamantyl) ethyl] -N- (3,3,3-trifluoropropyl) carbamic acid 3- (4-pyridyl) propyl ester (Compound 5-4)
[941] IR (neat): 2903, 2847, 1705, 1603, 1482, 1451, 1425 cm ^-1
[942] N- [2- (1-adamantyl) ethyl] -N- [2- [N '-(t-butoxycarbonyl) -N'-methylamino] ethyl] carbamic acid 3- (4- Pyridyl) propyl ester (Compound 5-5)
[943] IR (neat): 2903, 2847, 1699, 1603, 1480, 1424 cm ^-1
[944] N- [2- (1-adamantyl) ethyl] -N-pentylcarbamate methyl-3- (4-pyridyl) propyl ester (Compound 5-6)
[945] IR (neat): 2904, 2847, 1701, 1602, 1450, 1424, 1381 cm ^-1
[946] This compound preparation example 6
[947] 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] hexahydro-2,4-pyridindione hydrochloride (Compound 6-1)
[948] 1- [2- (1-adamantyl) ethyl] -1- [2- (t-butoxycarbonyl) ethyl] -3- [3- (4-pyridyl) propyl] urea of compound 1-69 4N hydrogen chloride 1,4-dioxane solution (2.5 ml) was added to (0.23 g, 0.49 mmol), and the mixture was stirred overnight at room temperature. After the reaction, the mixture was concentrated under reduced pressure, and 1N aqueous sodium hydroxide solution (20 ml) and ethyl acetate (30 ml) were added to the residue. The ethyl acetate layer was washed with water (20 ml) and saturated aqueous sodium chloride solution (20 ml), and dried over anhydrous magnesium sulfate. The oily product obtained after concentration under reduced pressure was dissolved in cyethyl ether (20 ml), 4N ethyl acetate acetate solution (0.50 ml, 2.00 mol) was added thereto under ice-cooling, concentrated under reduced pressure, and the precipitated solid was filtered out with ethyl acetate to obtain the target compound. 0.17 g (79%) was obtained.
[949] IR (KBr): 2902, 2437, 1710, 1666 cm ^-1
[950] mp: 177.0-178.5 ° C
[951] The following compounds were obtained by the same operation as in the present compound Preparation Example 6.
[952] 1- [2- (cyclohexyl) ethyl] -3- (4-pyridyl) methylhexahydro-2,4-pyrimidinedione hydrochloride (Compound 6-2)
[953] IR (KBr): 2925, 2850, 1718, 1671, 1600, 1493, 1450 cm ^-1
[954] mp: 64.0-74.5 ° C.
[955] 3- [2- (1-adamantyl) ethyl] -1- [3- (4-pyridyl) propyl] hexahydro-2,4-pyrimidinedione hydrochloride (Compound 6-3)
[956] IR (KBr): 2906, 2845, 1716, 1696, 1658, 1486 cm ^-1
[957] mp: 170 ℃
[958] Example compound production example 7
[959] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] thiourea (Compound 7-1)
[960] Anhydrous tetrahydrofuran of 4- (3-aminopropyl) pyridine (0.24 g, 1.8 mmol) of intermediate 2-1 in 1,1'-thiocarbonyldiimidazole (0.31 g, 1.8. Mmol) under a nitrogen atmosphere. 10 ml) was added and stirred at room temperature. After 1 hour, anhydrous tetrahydrofuran (10 ml) solution of 2- (1-adamantyl) -N-pentylethylamine hydrochloride (0.50 g, 1.8 mmol) of intermediate 1-1 was added and heated to reflux for 2.5 hours. After allowing to cool, ethyl acetate (50 ml) and saturated aqueous sodium hydrogen carbonate solution (50 ml) were added to the reaction solution for separation. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution (50 ml) and dried over anhydrous magnesium sulfate. After concentration under reduced pressure, purification by silica gel column chromatography gave 0.18 g (24%) of the target compound.
[961] IR (neat): 3304, 2902, 2846, 1603, 1530, 1345 cm ^-1
[962] The following compounds were obtained by the same operation as in the present compound Preparation Example 7.
[963] 1- (2-hydroxyethyl) -1-phenethyl-3- [3- (4-pyridyl) propyl] thiourea (Compound 7-2)
[964] IR (KBr): 3022, 2920, 2876, 1606, 1585 cm ^-1
[965] mp: 105.6-107.1 ° C.
[966] Example compound production example 8
[967] 1-phenethyl-3- [3- (4-pyridyl) propyl] -2-imidazolidinethione (Compound 8-1)
[968] 1- (2-hydroxyethyl) -1-phenethyl-3- [3- (4-pyridyl) propyl] thiourea (601 mg, 1.75 mmol), triphenylphosphine (913 mg) of compound 7-2 , 3.49 mmol) was added anhydrous tetrahydrofuran (2.5 ml), and the mixture was stirred under water / methanol. Anhydrous tetrahydrofuran solution of azodicarboxylic acid diisopropyl ester (710 mg, 3.49 mmol) was added dropwise and ethyl acetate (100 ml) was added after 10 minutes. Saturated sodium bicarbonate (40 ml) and saturated brine (40 ml) were washed in that order, dried over sodium sulfate, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, and the obtained solid was filtered out with hexane to give 107 mg (19%) of the target compound as crystals.
[969] IR (KBr): 3064, 3018, 2926, 2858, 1601, 1560, 1498, 1456 cm ^-1
[970] mp: 99.5-104.0 ° C.
[971] Example compound production example 9
[972] 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] hexahydropyrimidin-2-one (Compound 9-1)
[973] 1-hydroxybenzotriazole (1.15 g, 8.49 mmol), β-alanine ethyl ester hydrochloride (1.30 g, 8.49 mmol) in anhydrous methylene chloride (30.0 ml) solution of 1-adamantane acetate (1.50 g, 7.72 mmol) ), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (1.63 g, 8.49 mmol) and N-methylmorpholine (2.05 ml, 18.7 mmol) were added by ice-cooling, followed by stirring at room temperature overnight. . The reaction solution was concentrated under reduced pressure, and ethyl acetate (50 ml) was added to the residue. 10% aqueous citric acid solution (50 ml), water (50 ml), saturated aqueous sodium hydrogen carbonate solution (50 ml), water (50 ml), saturated aqueous sodium chloride solution (50 ml) and then dried over anhydrous magnesium sulfate. . Concentration under reduced pressure gave 2.48 g (quantitative) of 3- [1- (adamantyl) methylcarboxamide] propionate ethyl ester as a white individual.
[974] Subsequently, 3-[(1-adamantyl) methylcarboxamide] propionate ethyl ester (2.40 g, 8.18 mmol) is dissolved in ethanol (5 ml), and a 2N aqueous sodium hydroxide solution (4.50 ml, 9.00 mmol) is iced. After cooling, the mixture was stirred at room temperature for 2 hours. 2N hydrochloric acid (15 ml) was added to the reaction solution to make it weakly acidic, and then ethyl acetate (70 ml) was added and extracted. The organic layer was washed with water (50 ml) and saturated aqueous sodium chloride solution (50 ml), and dried over anhydrous magnesium sulfate. After concentration under reduced pressure, the precipitated solid was filtered out using diethyl ether to obtain 1.43 g (70.1%) of 3-[(1-adamantyl) methylcarboxamide] propionic acid.
[975] Then 1-hydroxybenzotriazole (0.83 g, 6.2 mmol) in anhydrous methylene chloride (10 ml) solution of 3-[(1-adamantyl) methylcarboxamide] propionic acid (1.4 g, 5.6 mmol), 1-ethyl-3- (3-dimethylaminopropyl) carboimide hydrochloride (1.2 g, 6.2 mmol), 4- (3-aminopropyl) pyridine (0.80 g, 5.9 mmol), N-methyl of intermediate 2-1 Morpholine (0.68 ml, 6.2 mmol) was added under ice cooling, followed by stirring at room temperature overnight. The reaction solution was concentrated under reduced pressure, ethyl acetate (50 ml) was added to the residue, followed by washing with saturated aqueous sodium hydrogen carbonate solution (30 ml), water (30 ml) and saturated aqueous sodium chloride solution (30 ml). Dried over magnesium sulfate. The precipitated solid was concentrated under reduced pressure and filtered out using diethyl ether to obtain 1.9 g (88%) of 3-[(1-adamantyl) methylcarboxamide] propionic acid 3- (4-pyridyl) propylamide. Could get
[976] Anhydrous diethyl ether (20 ml) was added to lithium aluminum hydride (0.45 g, 121 nmo1) under ice-cooling. Subsequently, anhydrous tetrahydrofuran (10 ml) solution of 3-[(1-adamantyl) methylcarboxamide] propionic acid 3- (4-pyridyl) propylamide (0.50 g, 1.3 mmol) was added dropwise for 15 minutes. Thereafter, the mixture was stirred overnight at room temperature, and further heated to reflux for 4.5 hours, and then added to the reaction solution carefully by adding 2 N aqueous sodium hydroxide solution (30 ml) and ethyl acetate (30 ml) under ice-cooling. The ethyl acetate layer was washed with water (30 ml) and saturated aqueous sodium chloride solution (30 ml) and dried over anhydrous magnesium sulfate. After concentration under reduced pressure, the residue was purified by silica gel column chromatography to give N- [2- (1-adamantyl) ethyl] -N '-[3- (4-pyridyl) propyl] -1,3-propane 0.05 g (10%) of diamine was obtained.
[977] Anhydrous methylene chloride of obtained N- [2- (1-adamantyl) ethyl] -N '-[3- (4-pyridyl) propyl] -1,3-propanediamine (8.0 mg, 0.23 mmol) (10 ml) solution and 1,1'-carbonyldiimidazole (40 mg, 0.26 mmol) solution of anhydrous methylene chloride (10 ml) were added dropwise to anhydrous methylene chloride (50 ml) with stirring at room temperature over 20 minutes. . After stirring overnight, the mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 8.0 mg (9.4%) of the titled compound.
[978] IR (neat): 3400, 2902, 2846, 1625, 1531, 1451 cm ^-1
[979] Example compound production example 10
[980] 1-acetylamino-1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10-1)
[981] 1- [2- (1-adamantyl) ethyl] -1-amino-3- [3- (4-pyridyl) propyl] urea dihydrochloride (0.20 g.0.47 mmol) of compound 3-3 at room temperature Pyridine (2.0 ml) and acetic anhydride (1.0 ml) were added, and it stirred for 15 minutes. The reaction solution was evaporated off under reduced pressure, and partitioned into ethyl acetate (10 ml) and water (10 ml). The organic layer was washed with saturated sodium bicarbonate water (10 ml) and saturated brine (10 ml), and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 0.11 g (58%) of the target compound.
[982] IR (KBr): 3374, 3163, 2907, 1694, 1638 cm ^-1
[983] mp: 140.0-146.0 ° C.
[984] The following compounds were obtained by the same operation as in the present compound Preparation Example 10. Moreover, the acid chloride was used as needed.
[985] 1- [2- (N-acetyl-N-methylamino) ethyl] -1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (compound 10-2)
[986] IR (neat): 3337, 2902, 1632, 1535, 1492 cm ^-1
[987] 1- [2- (1-adamantyl) ethyl] -1- [2- (N-isonicotinoyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] Urea (Compound 10-3)
[988] IR (neat): 3350, 2902, 2846, 1633, 1531, 1450, 1408 cm ^-1
[989] 1- [2- (1-adamantyl) ethyl] -1- [2- [N-methyl-N- (methylsulfonyl) amino] ethyl] -3- [3- (4-pyridyl) propyl Urea (Compound 10-4)
[990] IR (KBr): 3319, 2902, 2845, 1616, 1540, 1326, 1142 cm ^-1
[991] mp: 164.9-167.2 ° C
[992] 1- [2- (1-adamantyl) ethyl] -1- [2- [N-methyl-N- (p-tolylsulfonyl) amino] ethyl] -3- [3- (4-pyridyl ) Propyl] urea (compound 10-5)
[993] IR (neat): 3358, 2902, 2846, 1633, 1603, 1531, 1343, 1161 cm ^-1
[994] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (3,3-dimethylbutyryl) -N-methylamino] ethyl] -3- [3- (4- Pyridyl) propyl] urea (Compound 10-6)
[995] IR (KBr): 3325, 2906, 2845, 1652, 1616, 1534 cm ^-1
[996] mp: 101.4-102.4 ° C.
[997] 1- [2- (1-adamantyl) ethyl] -1- [2- (N-ethoxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] Urea (Compound 10-7)
[998] IR (neat): 3350, 2902, 2846, 1698, 1633, 1532 cm ^-1
[999] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) amino] ethyl] -3- [3- (4-pyridyl) propyl] Urea (Compound 10-8)
[1000] IR (KBr): 3312, 2905, 2845, 1710, 1637, 1606, 1534, 1269, 1249, 1174 cm ^-1
[1001] mp: 158.0-160.5 ° C.
[1002] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-ethylamino] ethyl] -3- [3- (4-pyri Dill) propyl] urea (compound 10-9)
[1003] IR (neat): 3349, 2902, 2846, 1693, 1667, 1633, 1603, 1531, 1452, 1416 cm ^-1
[1004] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (1,1-dimethyl-2,2,2-trichloroethoxycarbonyl) -N-methylamino] Ethyl] -3- [3- (4-pyridyl) propyl] urea (compound 10-10)
[1005] IR (neat): 3359, 2903, 2846, 1707, 1636, 1603, 1534 cm ^-1
[1006] mp: 47.0-52.0 ° C.
[1007] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (1,1-dimethylpropoxycarbonyl) -N-methylamino] ethyl] -3- [3- ( 4-pyridyl) propyl] urea (compound 10-11)
[1008] IR (neat): 3349, 2972, 2902, 2846, 1695, 1631, 1603, 1534, 1226, 1159 cm ^-1
[1009] 1- [2- (1-adamantyl) ethyl] -1- [2- (N-isopropoxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl Urea (Compound 10-12)
[1010] IR (neat): 3350, 2903, 2846, 1696, 1632, 1603, 1530 cm ^-1
[1011] (-)-1- [2- (1-adamantyl) ethyl] -1- [2- (N-mentoxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyri Dill) propyl] urea (compound 10-13)
[1012] IR (neat): 3350, 2904, 2847, 1694, 1633, 1603, 1530 cm ^-1
[1013] [α] ²⁰ _D : -27.5 ° (MeOH, C1.0)
[1014] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (3,3-dimethylbutyryl) -N-methylamino] ethyl] -3- [2-methyl-3 -(4-pyridyl) propyl] urea (compound 10-14)
[1015] IR (neat): 3324, 2902, 2846, 1633, 1537 cm ^-1
[1016] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- [2- (N'-isopropoxycarbonyl-N'-methylamino) ethyl] amide (Compound 10-15)
[1017] IR (neat): 3553, 2978, 2903, 2847, 1697, 1646 cm ^-1
[1018] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- [2- (N'-benzyloxycarbonyl-N'-methylamino) ethyl] amide ( Compound 10-16)
[1019] IR (neat): 3387, 3030, 2903, 2847, 1701, 1646, 1602, 1453, 1422 cm ^-1
[1020] 5- (4-pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- [2- [N '-(3,3-dimethylbutyryl) -N'-methylamino ] Ethyl] amide (Compound 10-17)
[1021] IR (neat): 3501, 2903, 2847, 1645, 1603, 1455, 1417 cm ^-1
[1022] Example compound production 11
[1023] 1- [2- (1-adamantyl) ethyl] -1,3-dimethyl-3- [3- (4-pyridyl) propyl] urea (Compound 11-1)
[1024] Under a nitrogen atmosphere, a trichloromethane (190 mg, 0.640 mmol) solution of dichloromethane (6.0 ml) was stirred at room temperature. Dichloromethane (6.0 ml) solution of 2- (1-adamantyl) -N-methylethylamine (330 mg, 1.71 mmol) and diisopropylethylamine (0.357 ml, 2.05 mmol) in intermediate 3-1 Dropped for a minute. After 8 minutes, dichloromethane (5.1 ml) solution of N-methyl-3- (4-pyridyl) propylamine (264 mg. 1.78 mmol) and diisopropylethylamine (0.357 ml, 2.05 mmol) in intermediate 3-3 Was added at once and stirred for 20 hours. The mixture was diluted with diethyl ether (40 ml), washed twice with saturated aqueous sodium hydrogen carbonate solution (40 ml), then washed with saturated aqueous sodium chloride solution (40 ml), and dried over magnesium sulfate. The solvent was evaporated off under reduced pressure and purified by silica gel column chromatography to obtain 335 mg (54%) of the target compound.
[1025] IR (neat): 2903, 2846, 1638, 1602, 1492 cm ^-1
[1026] Example Compound Preparation 12
[1027] 1- [2- (1-adamantyl) ethyl] -1-hydroxy-3- [3- (4-pyridyl) propyl] urea (Compound 12-1)
[1028] 1- [2- (1-adamantyl) ethyl] -1-benzyloxy-3- [3- (4-pyridyl) propyl] urea (438 mg, 0.978 mmol) of compound 1-28 (9.78) ml) 2N hydrochloric acid (4.0 ml) was added to the solution, and the nitrogen gas was vented. Palladium (43 mg) on carbon 10% was added, and it stirred for 3 days under 1 atmosphere of hydrogen. The palladium on carbon was filtered off, and the filtrate was concentrated under reduced pressure, and then diluted with diethyl ether (30 ml). After washing with saturated aqueous sodium hydrogen carbonate solution (30 ml) and saturated aqueous sodium chloride solution (30 ml), the mixture was dried over magnesium sulfate. The solvent was evaporated off under reduced pressure and purified by silica gel column chromatography to obtain 119 mg (34%) of the titled compound.
[1029] IR (KBr): 3438, 3152, 2903, 2847, 1650 cm ^-1
[1030] mp: 101.0-102.5 ° C.
[1031] This compound preparation example 13
[1032] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-1)
[1033] Chloroform (0.3 ml) of 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (200 mg, 0.486 mmol) of compound 1-1 To the solution was added 4N ethyl hydrochloride acetate solution (0.400 ml, 1.60 mmol). The solvent was evaporated under reduced pressure, and the precipitated solid was washed with ethyl acetate and filtered out. The obtained crude crystal was recrystallized from 2-butanone (5.0 ml) to obtain 94 mg (43%) of the target compound.
[1034] IR (KBr): 3322, 3050, 2902, 2496, 1621, 1534, 1450 cm ^-1
[1035] mp: 157.0-158.0 ° C.
[1036] The following compounds were obtained by the same operation as in the present compound Preparation Example 13.
[1037] 1- [2- (1-adamantyl) ethyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-2)
[1038] IR (neat): 3338, 2901, 2845, 1620, 1450 cm ^-1
[1039] 1- (2-cyclohexylethyl) -3- (4-pyridyl) methyl-1- (2-thienyl) methylurea hydrochloride (Compound 13-3)
[1040] IR (KBr): 3296, 2923, 1635, 1599, 1518 cm ^-1
[1041] mp: 161.8-164.4 ° C.
[1042] 1- [2- (1-adamantyl) ethyl] -1-butyl-3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-4)
[1043] IR (neat): 3331, 2901, 2845, 1754, 1636, 1537 cm ^-1
[1044] 1,1-bis [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-5)
[1045] IR (KBr): 3289, 2900, 2844, 1637, 1560 cm ^-1
[1046] mp: 120.0-122.5 ° C.
[1047] 1- [2- (1-adamantyl) ethyl] -1- (2-aminoethyl) -3- [3- (4-pyridyl) propyl] urea dihydrochloride (Compound 13-6)
[1048] IR (neat): 3358, 2902, 2846, 1634, 1538, 756 cm ^-1
[1049] 2- [2- (4-pyridyl) ethylamino] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide dihydrochloride (Compound 13-7)
[1050] IR (KBr): 3424, 2902, 1651 cm ^-1
[1051] mp: 133,7-137.0 ° C.
[1052] 3- [N'-methyl-N '-(4-pyridylmethyl) amino] propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide dihydrochloride (Compound 13-8)
[1053] IR (KBr): 3424, 2901, 2846, 1641 cm ^-1
[1054] 1,1-diisopentyl-3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-9)
[1055] IR (KBr): 3082, 2956, 2869, 2614, 1626, 1526 cm ^-1
[1056] mp: 120.5-131.7 ° C.
[1057] 1- [3- (1-adamantyl) propyl] -1-propyl-3- [3- (4-pyridyl) propyl] ureaphosphate (Compound 13-10)
[1058] IR (KBr): 3517, 3423, 1642, 1594, 1539, 1508 cm ^-1
[1059] mp: 148.0-149.0 ° C
[1060] Example compound production 14
[1061] 1- [2- (1-adamantyl) ethyl] -3- [3-hydroxy-3- (4-pyridyl) propyl] -1-pentylurea (Compound 14-1)
[1062] 1- [2- (1-adamantyl) ethyl] -3- [3- (t-butyldimethylsilyloxy) -3- (4-pyridyl) propyl] -1-pentylurea of compound 1-138 ( 136 mg, 0.250 mmol) of 10% hydrogen chloride and methanol solution (2.3 ml) was stirred at room temperature for 3 days. The solvent was evaporated under reduced pressure, and then partitioned into ethyl acetate (50 ml), water (30 ml) and 1N aqueous sodium hydroxide solution (2.0 ml), and the organic layer was washed with saturated aqueous sodium chloride solution (40 ml). After drying over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to obtain the target compound (59.2 mg, colorless amorphous powder, 55.3%).
[1063] IR (neat): 3339, 2904, 2847, 1622, 1605, 1532 cm ^-1
[1064] Example compound production example 15
[1065] Cis-1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridyl) cyclopropylmethyl] urea (Compound 15-1)
[1066] (Z) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] of compound 1-111 under ice-cold nitrogen atmosphere In anhydrous 1,2-dichloroethane (3 ml) solution of urea (0,25 g, 0,61 mmol), diethyl zinc 1.0M hexane solution (3.1 ml, 3.1 mmol) and chloroiomethane (0.44 ml, 6.1 mo1) ) Was added and stirred for 1 hour. Under ice-cooling, saturated ammonium chloride aqueous solution (10 ml) was added to the reaction solution, which was stirred at room temperature for 20 minutes, and then partitioned into ethyl acetate (20 ml) and saturated aqueous ammonium chloride solution (10 ml). The organic layer was washed with saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The solvent was evaporated off under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain 9.0 mg (3.5%) of the target compound as colorless crystals.
[1067] IR (KBr): 3340, 3025, 2903, 2847, 1617, 1603, 1525 cm ^-1
[1068] mp: 128.0-130.0 ° C
[1069] Example compound production 16
[1070] 4- [3- [3- [2- (1-adamantyl) ethyl] -3-pentylureido] propyl] pyridine N-oxide (Compound 16-1)
[1071] 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (3.0 g, 7.3 mmol) of compound 1-1 under room temperature nitrogen atmosphere M-chloro perbenzoic acid (2.5 g, 15 mmol) was added to the anhydrous dichloromethane (24 ml) solution, and it stirred overnight. The reaction solution was partitioned between chloroform (20 ml) and 1N aqueous sodium hydroxide solution (60 ml). The organic layer was washed with water (10 ml) and saturated aqueous sodium chloride solution (10 ml), and dried over anhydrous magnesium sulfate. The residue obtained by evaporating off the solvent under reduced pressure was purified by silica gel column chromatography to obtain 2.92 g (94.2%) of the target compound.
[1072] IR (KBr): 3346, 2902, 2845, 1622, 1538, 1217, 1178 cm ^-1
[1073] mp: 97.8-127.0 ° C.
[1074] Example compound production 17
[1075] 1- [2- (1-adamantyl) ethyl] -1- [2- [N- (2-methoxyethyl) -N-methylamino] ethyl] -3- [3- (4-pyridyl ) Propyl] urea (compound 17-1)
[1076] 1- [2- (1-adamantyl) ethyl] -1- (2-methylaminoethyl) -3- as a prebase of compound 3-1 in N, N-dimethylformamide (20 ml) at room temperature. [3- (4-Pyridyl) propyl] urea (1.50 g, 3.76 mmol), potassium carbonate (1.56 g, 11,3 mmol) and sodium iodide (1.69 g, 11.3 mmol) were added followed by 2-chloroethyl Methyl ether (412 μl, 4,51 mmol) was added and heated to 80 ° C. After stirring overnight, diethyl ether (50 ml) and water (100 ml) were added to the reaction mixture, and the obtained organic layer was washed with water (100 mL) and saturated aqueous sodium chloride solution (50 ml), and dried over anhydrous magnesium sulfate. After drying, it concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 552 mg (32.1%) of the target compound as a pale yellow oil.
[1077] IR (neat): 3350, 2901, 1643, 1602, 1531 cm ^-1
[1078] Example Compound Preparation 18
[1079] 2- [2- (4-pyridyl) ethylamino] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 18-1)
[1080] Bromoacetic acid (0.50 g, 3.6 mmol) was dissolved in anhydrous tetrahydrofuran (20 ml) and stirred at 115 ° C. under a nitrogen atmosphere. N-methylmorpholine (0.40 ml, 3.6 mmol) and isobutyl chlorocarbonate (0.45 ml, 3.5 mmol) were added thereto. Then, anhydrous tetrahydrofuran (20 ml) solution which is a prebase of 2- (1-adamantyl) -N-pentylethylamine hydrochloride (1.0 g, 3,5 mmol) as intermediate 1-1 was added dropwise. After stirring at 0 degreeC for 1.5 hours, saturated sodium bicarbonate aqueous solution (70 ml) and ethyl acetate (70 ml) were added and distributed to the reaction liquid. The ethyl acetate layer was washed with water (70 ml) and saturated aqueous sodium chloride solution (70 ml), and dried over anhydrous magnesium sulfate. Concentration under reduced pressure yielded 1.3 g (quantitative) of 2-bromoacetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide as an oily substance.
[1081] Subsequently, 2-bromoacetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.3 g, 3.5 mmol) is dissolved in anhydrous N, N-dimethylformamide (30 ml), Potassium carbonate (1.5 g, 11 mmol), methyl iodide (1.6 g, 11 mmol), 4- (2-aminoethyl) pyridine (0.43 g, 3.5 mmol) were added, and the mixture was stirred overnight at an external temperature of 75 ° C. Water (100 ml) and diethyl ether (100 ml) were added to the reaction mixture, and the diethyl ether layer was washed twice with water (70 ml) and once with saturated aqueous sodium chloride solution (120 ml). Dried over magnesium. Concentration under reduced pressure and purification by silica gel column chromatography gave 0.6 g (40%) of the target compound as an oily substance.
[1082] IR (neat): 3312, 2902, 2846, 1651, 1602, 1454 cm ^-1
[1083] The following compounds were obtained by the same operation as in the present compound preparation example 18.
[1084] 3- [N'-Methyl-N '-(4-pyridylmethyl)] aminopropionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 18-2)
[1085] IR (neat): 2902, 2846, 1643 cm ^-1
[1086] 2- [2- (4-pyridyl) ethoxy] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 18-3)
[1087] IR (neat): 2902, 2846, 1650, 1602, 1451, 1113 cm ^-1
[1088] Example compound production example 19
[1089] (R) -1- [2- (4-pyridyl) ethyl] -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide hydrochloride (Compound 19 -One)
[1090] N-t-butoxycarbonyl-L-proline (1.7 g, 8.0 mmol) was dissolved in anhydrous tetrahydrofuran (20 ml) and stirred at -15 ° C under nitrogen atmosphere. N-methylmorpholine (0.90 ml, 8.0 mmol) and isobutyl chlorocarbonate (1.0 ml, 8.0 mmol) were added to this. After 10 minutes, an anhydrous tetrahydrofuran (20 ml) solution of prebase (2.0 g, 8.0 mmol) of intermediate 1-1 was added dropwise over 5 minutes. After stirring at 0 degreeC for 45 minutes, it returned to room temperature and stirred overnight. A saturated aqueous sodium hydrogen carbonate solution (50 ml) and ethyl acetate (50 ml) were added to the reaction mixture, and the mixture was partitioned. The ethyl acetate layer was washed with 10% aqueous citric acid solution (50 ml), water (50 ml) and saturated aqueous sodium chloride solution (50 ml), and dried over anhydrous magnesium sulfate. Concentration under reduced pressure and purification by silica gel column chromatography gave (R) -1- (t-butoxycarbonyl) -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) of the target compound. 1.9 g (52%) of ethyl] -N-pentylamide were obtained as an oil.
[1091] Then (R) -1- (t-butoxycarbonyl) -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.8 g, 4.0 mmol) ), 4N hydrogen chloride / dioxane (20 ml, 81 mmol) was added under ice-cooling, and the mixture was returned to room temperature and stirred for 1.5 hours. Concentration under reduced pressure yielded 1.5 g (quantitative) of (R) -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide hydrochloride as an amorphous form.
[1092] Subsequently, (R) -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide hydrochloride (1.4 g, 3.7 mmol) was substituted with anhydrous N, N-dimethylformamide. (40 ml), potassium carbonate (2.6 g, 19 mmol), methyl iodide (1.7 g, 11 mmol), and 4- (2-chloroethyl) pyridine hydrochloride (0.70 g, 3.7 mmol) were added, followed by external temperature 80 It stirred at C overnight. 2N aqueous sodium hydroxide solution (70 ml) and diethyl ether (70 ml) were added to the reaction mixture, and the diethyl ether layer was washed with water (70 ml) and saturated aqueous sodium chloride solution (70 ml), and dried over anhydrous magnesium sulfate. Dried. Concentration under reduced pressure and purification by silica gel column chromatography gave the target compound 0.809 (47%) as an oily substance.
[1093] IR (neat): 2902, 2846, 1644 cm ^-1
[1094] [α] ²⁰ _D : -48.1 ° (MeOH, C1.0)
[1095] The following compounds were obtained by the same operation as in Production Example 19 of the compound.
[1096] (S) -1- [2- (4-pyridyl) ethyl] -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide hydrochloride (Compound 19 -2)
[1097] IR (neat): 2902, 2846, 1644, 1601 cm ^-1
[1098] [α] ²⁰ _D : + 41.6 ° (MeOH, C1.0)
[1099] Example compound production example 20
[1100] 1- [2- (1-adamantyl) ethyl] -1- [2- (N-ethylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 20-1)
[1101] Lithium aluminum hydride (890 mg, 23.5 mmol) was suspended in anhydrous diethyl ether (10 ml) under a nitrogen atmosphere, and then cooled under ice and 1- [2- (acetylamino) ethyl] -1 of compound 1-103 while stirring. -Anhydrous tetrahydrofuran (60 ml) solution of [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (4.86 g, 11.4 mmol) over 2 hours It dripped and returned to room temperature and stirred for 70 hours. Ethyl acetate (25 ml) was added by ice-cooling, 1N sodium hydroxide aqueous solution (25 ml) was added, and insoluble matter was removed by Celite filtration. The filtrate was partitioned between ethyl acetate (25 ml) and water (25 ml), and the organic layer was washed with saturated aqueous sodium chloride solution (20 ml). After drying over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure to purify the residue by silica gel column chromatography to obtain the target compound (2.33 g, colorless crystals, 49.8%).
[1102] IR (KBr): 3309, 2901, 2845, 1615, 1534 cm ^-1
[1103] mp: 96.8-104.9 ° C.
[1104] This compound preparation example 21
[1105] 3- (4-Pyridylmethylideneamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 21-1)
[1106] 3- (t-butoxycarbonylamino) propionic acid (1.0 g, 5.3 mmol) was dissolved in anhydrous tetrahydrofuran (15 ml) and N-methylmorpholine (0.6 ml, 5.5 mmol) was added and stirred at -15 ° C. Isobutyl chlorocarbonate (0.7 ml, 5.4 mmol) was added. An anhydrous tetrahydrofuran (15 ml) solution of a prebase of 2- (1-adamantyl) -N-pentylethylamine hydrochloride (1.5 g, 5.3 mmol) of intermediate 1-1 was then added at -18 ° C. After stirring at 0 ° C. for 1.5 hours, ethyl acetate (100 ml) and saturated aqueous sodium hydrogen carbonate solution (100 ml) were added and distributed. 10% aqueous citric acid solution (100 ml), water (100 ml), saturated aqueous sodium chloride solution (100 ml) and washed with anhydrous magnesium sulfate. Concentration under reduced pressure and purification by silica gel column chromatography gave 1.9 g (85%) of 3- (t-butoxycarbonylamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide as an oil phase. Obtained as a substance.
[1107] 4.0N hydrogen chloride / 1,4-di under ice-cooling 3- (t-butoxycarbonylamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.9 g, 4.4 mmol) After adding a oxane solution (22 ml, 88 mmol), it returned to room temperature and stirred for 1 hour and 15 minutes. Concentration under reduced pressure afforded 1.4 g (89%) of hydrochloride as the target. 1N aqueous sodium hydroxide solution (80 ml) was added thereto, and the mixture was extracted with chloroform (80 ml). The chloroform layer was washed with saturated aqueous sodium chloride solution (80 ml), and dried over anhydrous magnesium sulfate. Concentration under reduced pressure gave 3-aminopropionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide as an oily substance.
[1108] 3-Aminopropionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.3 g, 3.9 mmol) was dissolved in anhydrous tetrahydrofuran (10 ml) and stirred under ice-cooling. 4-pyridinecarboxyaldehyde (0.42 ml, 4.3 mmol) was added thereto, followed by stirring at room temperature for 3 hours. Concentration under reduced pressure afforded 1.7 g (quantitative) of the target compound as an oily substance.
[1109] IR (neat): 2901, 1713, 1644, 1454 cm ^-1
[1110] Example Compound Preparation 22
[1111] 3- (4-Pyridylmethylamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 22-1)
[1112] 3- (4-Pyridylmethylideneamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.6 g, 3.9 mmol) of the compound 21-1 was dissolved in methanol, and the catalytic amount Palladium on carbon was added and stirred at room temperature under 1 atmosphere of hydrogen for 7 hours. Palladium on carbon 10% was filtered off, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain 0.58 g (36%) of the titled compound as an oil.
[1113] IR (neat): 3313, 2902, 2846, 1636, 1451 cm ^-1
[1114] This compound preparation example 23
[1115] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-cyano) pyridyl] propyl] -1-pentylurea (Compound 23-1)
[1116] 4- [3- [3- [2- (1-adamantyl) ethyl] -3-pentylureido] propyl] pyridine N-oxide of compound 16-1 under room temperature nitrogen atmosphere (1.0 g, 2.3 mmol) Trimethylsilyl cyanide (1.2 ml, 9.4 mmol) and triethylamine (0.65 ml, 4.7 mmol) were added to anhydrous acetonitrile (1.5 ml) solution, and the mixture was heated to reflux overnight. The reaction solution was partitioned between chloroform (40 ml) and saturated aqueous sodium hydrogen carbonate solution (40 ml). The organic layer was washed with saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. 730 mg (73.0%) of the target compound were obtained by filtering out the crystal | crystallization with the diisopropyl ether the residue obtained by evaporating a solvent under reduced pressure.
[1117] IR (KBr): 3334, 2900, 2845, 2234, 1621, 1534 cm ^-1
[1118] mp: 112.0-123.0 ° C.
[1119] Example compound production example 24
[1120] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-aminomethyl) pyridyl] propyl] -1-pentylurea (compound 24-1)
[1121] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-cyano) pyridyl] propyl] -1-pentylurea of compound 23-1 under room temperature nitrogen atmosphere A catalytic amount of 10% carbonaceous palladium was added to a 0.20 g, 0.46 mmol) methanol (2.0 ml) solution, followed by stirring overnight under a hydrogen atmosphere. After the reaction solution was filtered through celite, the solvent was evaporated off under reduced pressure, and the resulting residue was partitioned between diethyl ether (50 ml) and water (50 ml). 2N aqueous sodium hydroxide solution (10 ml) was added to the aqueous layer, followed by further extraction with diethyl ether (50 ml). The combined organic layers were washed with saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was filtered off with diisopropyl ether to obtain 151 mg (74.4%) of the target compound.
[1122] IR (KBr): 3346, 2901, 2845, 1621, 1538 cm ^-1
[1123] mp: 88.0-95.0 ° C.
[1124] Example compound production 25
[1125] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-carboxy) pyridyl] propyl] -1-pentylurea (Compound 25-1)
[1126] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-cyano) pyridyl] propyl] -1-pentylurea (0.20 g of compound 23-1 at room temperature , 0.46 mmol) was added 6N hydrochloric acid (1.5 ml, 9.2 mmol) and heated to reflux overnight. The reaction solution was evaporated off under reduced pressure, and the crystals were filtered out with acetone. It was dissolved in chloroform (40 ml) and washed with water (40 ml) and saturated aqueous sodium chloride solution (10 ml). The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated off under reduced pressure to obtain 132 mg (63.0%) of the target compound.
[1127] IR (KBr): 3326, 2905, 2848, 1704, 1621, 1539 cm ^-1
[1128] mp: 130 ° C.
[1129] Example Compound Preparation 26
[1130] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-hydroxymethyl) pyridyl] propyl] -1-pentylurea (Compound 26-1)
[1131] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-carboxy) pyridyl] propyl] -1-pentylurea (0.10) of compound 25-1 under nitrogen atmosphere ice-cooling g, 0.22 mmol) of anhydrous tetrahydrofuran (0.7 ml) was added borane-tetrahydrofuran complex 1.0M tetrahydrofuran solution (0.66 ml, 0.661 mmol) and stirred for 4.5 hours at room temperature. Water (3 ml) was added to the reaction solution under ice-cooling, and then partitioned into ethyl acetate (15 ml) and 0.1% aqueous sodium hydroxide solution (10 ml). The organic layer was washed with saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The residue obtained by evaporation of the solvent under reduced pressure was purified by silica gel column chromatography to obtain 53 mg of borane complex salt of the target compound as an oily substance.
[1132] IR (neat): 3342, 2904, 1630, 1531 cm ^-1
[1133] This compound preparation example 27
[1134] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-methyl) pyridyl] propyl] -1-pentylurea (Compound 27-1)
[1135] 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-hydroxymethyl) pyridyl] propyl] -1-pentylurea (50 of compound 26-1 at room temperature. To anhydrous dichloromethane (1.0 ml) solution of mg, 0.11 mmol) and triethylamine (20 μl, 0.13 mmol) was added p-toluenesulfonyl chloride (23 mg, 0.12 mmol) and stirred overnight at room temperature. The reaction solution was partitioned between chloroform (9 ml) and water (10 ml), and the organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated off under reduced pressure, and the obtained residue was purified by silica gel column chromatography. A catalytic amount of 10% palladium on carbon was added to a methanol (1 ml) solution of the obtained p-toluenesulfonyl compound, and the target compound 18 mg (38%) was obtained as an oily substance by stirring for 7 days in a hydrogen atmosphere.
[1136] IR (neat): 3345, 2903, 2847, 1624, 1534 cm ^-1
[1137] Example Compound Preparation 28
[1138] 1- [2- (1-adamantyl) ethyl] -1- (2-aminoethyl) -3- [3- (4-pyridyl) propyl] urea (Compound 28-1)
[1139] Under ice-cooling, 1- [2- (acetylamino) ethyl] -1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea of compound 1-103 was obtained. 6N hydrochloric acid (15 ml) was added to a 1.02 g, 2.39 mmol) methanol (10 ml) solution, and the mixture was heated and stirred at 90 ° C for 3 days. The reaction solution was neutralized with 1N aqueous sodium hydroxide solution (10 ml), and chloroform (50 ml) and water (10 ml) were added and partitioned. The organic layer was washed with saturated aqueous sodium chloride solution (50 ml), dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. Purification of the residue by silica gel column chromatography gave 200 mg (21.7%) of the target compound as an oil.
[1140] IR (neat): 3306, 2902, 2846, 1629, 1605, 1537, 753 cm ^-1
[1141] This compound preparation example 29
[1142] 4- [2- [N- [2- (1-adamantyl) ethyl] -N-pentylcarbonylmethoxy] ethoxy] pyridine N-oxide (Compound 29-1)
[1143] Under ice-cooling, in anhydrous dichloromethane (6 ml) solution of diglycolyl chloride (0.31 ml, 2.6 mmol) and triethylamine (0.70 ml, 5.1 mmol), 2- (1-adamantyl)-of intermediate 1-1 N-pentylethylamine hydrochloride (0.50 g, 1.7 mmol) was added and the mixture was stirred overnight at room temperature. Methanol (5 ml) was added to the reaction solution, and the mixture was stirred for 3 hours. After evaporation of the solvent under reduced pressure, the mixture was partitioned between ethyl acetate and water (15 ml each), and the organic layer was washed with saturated aqueous sodium chloride solution (5 ml) and dried over anhydrous magnesium sulfate. 0.39 g (60) of 2-methoxycarbonylmethoxyacetic acid N- [2- (1-adamantyl) ethyl] -1-pentylamide by purifying the solvent by evaporation under reduced pressure, and the obtained residue was purified by silica gel column chromatography. %) Was obtained as an oily substance.
[1144] Then, on ice-cooling, sodium borohydride (0.18 g, 4.8 mmol) was added to a methanol (3 ml) solution of N- [2- (1-adamantyl) ethyl] -1-pentylamide (0.37 g, 0.96 mmol). It was added and stirred overnight at room temperature. Water (10 ml) was added to the reaction mixture, which was stirred for 10 minutes, followed by partitioning by adding water (20 ml) and ethyl acetate (30 ml). The organic layer was washed with saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. 74 mg of 2- (2-hydroxyethoxy) acetic acid N- [2- (1-adamantyl) ethyl] -1-pentylamide was purified by evaporation of the solvent under reduced pressure, and the residue was purified by silica gel column chromatography. (22%) was obtained as an oily substance.
[1145] Then N, N-dimethylformamide of 2- (2-hydroxyethoxy) acetic acid N- [2- (1-adamantyl) ethyl] -1-pentylamide (60 mg, 0.17 mmol) at room temperature. 4-nitropyridine N-oxide (24 mg, 0.17 mmol) and potassium carbonate (28 mg, 0.20 mmol) were added to the solution (0.4 ml), and the mixture was stirred at 6 ° C for 2 days. The reaction solution was evaporated off under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain 39 mg of the target compound as an oil.
[1146] 1 H-NMR (400 MHz, CDCl ₃ ) δ 0.87-0.93 (m, 3H), 1.20-1.40 (m, 6H), 1.47-1.60 (m, 8H), 1.61-1.67 (m, 3H), 1.68- 1,76 (m, 3H), 1.97 (brs, 3H), 3,10-3.19 (m, 2H), 3.25-3.36 (m, 2H), 3.94-3.98 (m, 2H), 4.20-4.27 (m , 4H), 6.81-6.86 (m, 2H), 8.10-8.15 (m, 2H)
[1147] This compound preparation example 30
[1148] 2- [2- (4-pyridyloxy) ethoxy] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 30-1)
[1149] 4- [2- [N- [2- (1-adamantyl) ethyl] -N-pentylcarbonylmethoxy] ethoxy] pyridine N-oxide of compound 29-1 at room temperature under nitrogen atmosphere (39 mg, 0.088 mmol), a catalytic amount of 10% carbonaceous palladium was added to a mixed solution of methanol (0.4 ml) and acetic acid (0.1 ml) of acetic anhydride (20 µl, 0.18 mmol) and stirred for 4 days under a hydrogen atmosphere. After celite filtration, the reaction solution was evaporated off under reduced pressure, and partitioned into ethyl acetate (20 ml) and saturated aqueous sodium hydrogen carbonate solution (20 ml). The organic layer was washed with saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The residue obtained by solvent evaporation removal was purified by silica gel column chromatography to give 16 mg (42%) of the target compound as an oil.
[1150] IR (neat): 2903, 1651, 1592 cm ^-1
[1151] Example Compound Preparation 31
[1152] 1- [2- (1-adamantyl) ethyl] -3- [3-oxo-3- (4-pyridyl) propyl] -1-pentylurea (Compound 31-1)
[1153] Under ice-cooling, compound 14-11- [2- (1-adamantyl) ethyl] -3- [3-hydroxy-3- (4-pyridyl) propyl] -1-pentylurea (100 mg, 0.234 mmol 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3 (1H) -one (221 mg, 0.520 mmol) in anhydrous dichloromethane (2 ml) solution The mixture was returned to room temperature and stirred for 1 hour. The mixture was further cooled with ice, ethyl acetate (10 ml), saturated aqueous sodium sulfite solution (5 ml) and saturated aqueous sodium hydrogen carbonate solution (5 ml) were added, followed by stirring for 15 minutes. The reaction mixture was partitioned between ethyl acetate (50 ml) and water (10 ml), and the organic layer was washed with saturated aqueous sodium sulfite solution (5 ml), saturated aqueous sodium hydrogen carbonate solution (5 ml) and saturated aqueous sodium chloride solution (25 ml). Washed. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated off under reduced pressure to obtain 87.3 mg (87.8%) colorless crystals of the target compound.
[1154] IR (KBr): 3328, 2901, 2847, 1710, 1619, 1540 cm ^-1
[1155] mp: 103.5-104.0 ° C.
[1156] [C] Formulation Example
[1157] An example of prescription of eye drops of this compound is shown below.
[1158] Prescription 1 (in 100 ml)
[1159] 100 mg of the present compound
[1160] Sodium chloride 900 mg
[1161] Polysorbate 80 proper
[1162] Sodium Hydroxide
[1163] Hydrochloric acid
[1164] Sterile water
[1165] Desired eye drops can be obtained by appropriately changing the mixing ratio of the present compound and the additive.
[1166] [D] pharmacological examination
[1167] (1) Angiogenesis Inhibition Test Using Human Vascular Endothelial Cells
[1168] In vitro angiogenesis evaluation model for cell proliferative responses induced by treatment of vascular endothelial growth factor (VEGF) in normal human umbilical vein endotherial cells (HUVECs). A VEGF-induced HUVEC proliferative response assay to measure the inhibitory effects of drugs is reported in Cancer Res., 59, 99-106 (1999). Therefore, the effect in the angiogenesis evaluation system of this compound was examined by the method according to the method of the said literature.
[1169] (Preparation of Test Compound)
[1170] This compound was dissolved in DMS0 and diluted with medium to obtain a solution of each test compound of 40 µM.
[1171] (Experimental method)
[1172] HUVECs prepared at 4 × 10 ⁴ cells / mL were seeded in 50 μL in 96-well plates coated with type I collagen to give 2 × 10 ³ cells / well. One day later, 25 μL of 0.8% DMS0 solution of test compound and 0.8% DMS0 solution as control were added to each well (containing 10 μM of each test compound and 0.2% DMSO as final concentration). One hour after drug addition, 40 ng / mL of VEGF solution was added to each well 25 μL (containing 10 ng / mL of VEGF as final concentration). Three days after VEGF addition, 10 µL of WST-8 assay reagent was added to each well, and the absorbance at 450 nm was measured.
[1173] (Evaluation result of angiogenesis)
[1174] The percentage of inhibition of cell proliferation relative to the control group was calculated, and the angiogenesis inhibition rate of most test compounds was 80% or more. These results are shown in Table 1.
[1175] Test substance% InhibitionTest substance% Inhibition Compound 1-183.4Compound 1-11881.6 Compound 1-2482.1Compound 1-12083.1 Compound 1-2583.2Compound 1-13783.3 Compound 1-2679.2Compound 1-13983.1 Compound 1-3583.7Compound 2-1483.4 Compound 1-10083.0Compound 2-1583.3 Compound 1-10783.2Compound 2-1882.2 Compound 1-11183.1Compound 2-2082.5 Compound 1-11283.2
[1176] (2) Angiogenesis inhibition test by high oxygen load-induced retinal angiogenesis method
[1177] As a model for evaluating in vivo retinal angiogenesis, a model for evaluating angiogenesis-inhibitory effects of drugs induced by high oxygen loading in neonatal rats is Arch Ophthalmol, 114 , 1210-12-17. 1996). Thus, the effects in the angiogenesis evaluation model of this compound were examined in accordance with the method described in the above document.
[1178] (Preparation of Test Compound)
[1179] The compound was suspended in phosphate buffer (PBS) containing 0.4% Tween80 to give a test compound suspension of 10 mg / ml.
[1180] (Experimental method)
[1181] Newborn rats several hours after birth were bred for 11 days in a high-oxygen-loaded breeding box maintained at 80% oxygen with parental rats, and returned to normal breeding conditions at 11 days of age. Was returned to normal breeding conditions once a day for 30 minutes.).
[1182] The test compound (200 μg / 20 μl / eye) was administered subconjunctival under avertin anesthesia for 11 days after the birth. Rats were euthanized by neembutal administration on the 18th day of age (P18), and the eyes were extracted. After removing the fixed eye 4% paraformaldehyde, the retina was separated. The separated retina was stained with ADPase, and the degree of angiogenesis was evaluated by the following angiogenesis evaluation method. In addition, PBS (2 μl / eye) containing 0.4% Tween80 was administered subconjunctivally instead of the test compound as a control of the model rat, and the same operation was performed.
[1183] The retinas stained with ADPase were divided into four quadrants and evaluated under an optical microscope. Evaluation was performed by scoring each upper limit according to the following evaluation criteria.
[1184] (Evaluation standard)
[1185] 0: There were no neovascular shoots and subsequent vascular bumps
[1186] 1: there were less than 5 neovascular shoots
[1187] 2: there were more than six neovascular shoots, or short vascular bumps
[1188] 3: there was less than half of one quadrant
[1189] 4: There was more than half of one upper vascular ridge
[1190] (Evaluation result of angiogenesis)
[1191] Angiogenesis inhibition rate [%] was calculated from the total point which added the number of each upper limit (in addition, the angiogenesis inhibition rate was made into the average value of each 9-12 cases), and the angiogenesis inhibition rate of most test compounds was 40% or more. .
[1192] As is clear from the results of the pharmacological test described above, the compound has an excellent angiogenesis inhibitory effect in any test in vitro and in vivo, and thus diseases involving angiogenesis, in particular, diabetic retinopathy, prematurity retinopathy, macular degeneration, It can be applied as a prophylactic and therapeutic agent for angiogenic glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascularization, solid tumor, hemangioma, tumor proliferation and metastasis.

权利要求:
Claims (24)
[1" claim-type="Currently amended] An angiogenesis inhibitor comprising the compound represented by the following general formula [1] or its salt as an active ingredient.

[Wherein, A represents — (NR ⁴ ) —, — (CR ⁵ R ⁶ ) — or —O—; B is -O-, -S-,-(NR ⁷ )-, -CO-, -N = or

The alkylene group or alkenylene group which may contain may be substituted, and this alkylene group and alkenylene group may be substituted by the hydroxyl group, the alkoxy group, the cycloalkyl group, the aryl group, the siloxy group, or the saturated or unsaturated heterocyclic ring, and it couple | bonds with A and saturated May form a heterocyclic ring;
R ¹ , R ² , R ⁴ , R ⁵ and R ⁶ are the same or different and represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group, an acyl group or an amino group and the corresponding alkyl group, alke The alkyl group, alkynyl group, cycloalkyl group or cycloalkenyl group is a halogen atom, hydroxy group, amino group, cycloalkyl group, adamantyl group, aryl group, carboxyl group, alkoxycarbonyl group, aryloxycarbonyl group, aminocarbonyl group, cyano group or saturated or unsaturated heterocyclic ring May be substituted with;
R ¹ and R ² , R ² and R ⁴ , R ² and R ^5, and R ² and R ⁶ may form a saturated or unsaturated heterocycle;
R ³ represents an aryl group or an unsaturated heterocycle;
R ⁷ represents a hydrogen atom or an alkyl group;
X represents = 0 or = S;
n represents an integer of 1 to 5;
The hydrogen atom of each amino group, hydroxy group and aminocarbonyl group described above is an alkyl group, a cycloalkyl group, adamantyl group, adamantylalkyl group, aryl group, arylalkyl group, acyl group, alkoxyalkyl group, alkoxycarbonyl group, alkylaminocarbonyl group, cycloalkyloxycarbonyl group Even when substituted with an arylalkoxycarbonyl group, alkylsulfonyl group, arylsulfonyl group, halogenoalkyloxycarbonyl group, imidazolylcarbonyl group, pyridylcarbonyl group, saturated or unsaturated hetero ring, or alkyl group substituted with saturated or unsaturated hetero ring good.] [2" claim-type="Currently amended] The angiogenesis inhibitor according to claim 1, comprising a compound or a salt thereof, wherein R ³ is a pyridine ring, as an active ingredient.
[3" claim-type="Currently amended] A compound according to claim ¹ , wherein at least one of R ¹ , R ² , R ⁴ , R ⁵ and R ⁶ is an adamantylalkyl group, adamantyloxyalkyl group, adamantylaminoalkyl group or adamantylaminocarbonylalkyl group Or salts thereof as an active ingredient.
[4" claim-type="Currently amended] The compound or a salt thereof according to claim 1, wherein at least one of R ¹ and R ² is an adamantylalkyl group, adamantyloxyalkyl group, adamantylaminoalkyl group, or adamantylaminocarbonylalkyl group. Angiogenesis inhibitor.
[5" claim-type="Currently amended] The angiogenesis inhibitor according to claim 1, wherein the active agent comprises a compound or a salt thereof, wherein at least one of R ¹ and R ² is an adamantylalkyl group.
[6" claim-type="Currently amended] The compound of claim 1, wherein A represents — (NR ⁴ ) —, — (CR ⁵ R ⁶ ) — or —O—;
B is -O-, -S-,-(NR ⁷ )-, -CO-, -N = or

It may represent an alkylene group or alkenylene group which may contain, and the alkylene group may be substituted with a hydroxy group, an alkoxy group, an aryl group, a siloxy group or a saturated or unsaturated heterocyclic ring, or may be combined with A to form a saturated heterocyclic ring. Good
R ¹ represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group or an amino group, and the alkyl group, alkenyl group, alkynyl group, cycloalkyl group or cycloalkenyl group is a halogen atom, a hydroxy group, an amino group, The cycloalkyl group, the aryl group, the carboxyl group, the alkoxycarbonyl group, the alkylaminocarbonyl group, the adamantyl group, the aryloxycarbonyl group, the cyano group, or the saturated or unsaturated heterocyclic ring may be substituted, and the hydrogen atoms of the above-described amino, hydroxyl and aminocarbonyl groups. Substituted with an alkyl group, a cycloalkyl group, an aryl group, an arylalkyl group, an acyl group, an alkoxycarbonyl group, a cycloalkyloxycarbonyl group, an arylalkoxycarbonyl group, a halogenoalkyloxycarbonyl group, an imidazolylcarbonyl group, an unsaturated heterocyclic ring or an unsaturated heterocyclic ring May be substituted with an alkyl group. ,
R ² represents an adamantylalkyl group, adamantyloxyalkyl group, adamantylaminoalkyl group, or adamantylaminocarbonylalkyl group;
R ³ represents an unsaturated heterocycle;
R ⁴ represents a hydrogen atom, an alkyl group, adamantylalkyl group, carboxyalkyl group, alkoxycarbonyl group, alkoxycarbonylalkyl group, amino group, alkylamino group, acylamino group or alkoxycarbonylamino group;
R ⁵ and R ⁶ are the same or different and represent a hydrogen atom, an alkyl group, an amino group or an alkoxycarbonylamino group;
R ⁷ represents a hydrogen atom or an alkyl group;
X represents = O or = S;
The angiogenesis inhibitor which contains as a active ingredient the compound or its salt which n represents the integer of 1-5.
[7" claim-type="Currently amended] The angiogenesis inhibitor according to claim 6, wherein R ² represents an adamantylalkyl group and R ³ contains a compound or a salt thereof that represents a pyridine ring as an active ingredient.
[8" claim-type="Currently amended] The compound of claim 6, wherein A represents — (NR ⁴ ) —, — (CR ⁵ R ⁶ ) — or —O—;
B is -S- or

It may represent an alkylene group or alkenylene group which may contain;
R ¹ represents an alkyl group or an alkenyl group, the alkyl group may be substituted with a halogen atom or an amino group, and the amino group may be substituted with an alkyl group, acyl group, arylalkyloxycarbonyl group, cycloalkyloxycarbonyl group or alkoxycarbonyl group;
R ² represents an adamantylalkyl group;
R ³ represents a pyridine ring;
R ⁴ represents a hydrogen atom;
R ⁵ and R ⁶ represent a hydrogen atom;
X represents = O;
The angiogenesis inhibitor which contains as a active ingredient the compound or its salt which n represents the integer of 1-5.
[9" claim-type="Currently amended] The compound of claim 1, wherein A represents — (NR ⁴ ) —, — (CR ⁵ R ⁶ ) — or —O—;
B is -O-, -S-,-(NR ⁷ )-, -N = or

Or an alkylene group or alkenylene group which may contain, the alkylene group may be substituted with a hydroxy group, an alkoxy group, an aryl group or a saturated or unsaturated heterocycle, or may be combined with A to form a saturated heterocycle;
R ¹ represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group or an amino group, and the alkyl group, alkenyl group, alkynyl group, cycloalkyl group or cycloalkenyl group is a halogen atom, a hydroxy group, an amino group, The cycloalkyl group, the aryl group, the carboxyl group, the alkoxycarbonyl group, the aryloxycarbonyl group, the aminocarbonyl group, the cyano group or the saturated or unsaturated heterocyclic ring may be substituted, and the hydrogen atom of each of the amino groups, hydroxy groups and aminocarbonyl groups described above is an alkyl group, a cycloalkyl group. Or an alkyl group substituted with an aryl group, an arylalkyl group, an acyl group, an alkoxycarbonyl group, a cycloalkyloxycarbonyl group, an arylalkoxycarbonyl group, an unsaturated heterocyclic ring or an unsaturated heterocyclic ring;
R ² represents an alkyl group, an alkenyl group, a cycloalkyl group, a cycloalkylalkyl group or an arylalkyl group;
R ³ represents a pyridine ring;
R ⁴ represents a hydrogen atom, an alkyl group, an adamantylalkyl group, a carboxyalkyl group, an alkoxycarbonylalkyl group, an amino group, an alkylamino group, an acylamino group or an alkoxycarbonylamino group;
R ⁵ and R ⁶ are the same or different and represent a hydrogen atom or an alkyl group;
R ⁷ represents a hydrogen atom or an alkyl group;
X represents = O or = S;
The angiogenesis inhibitor which contains as a active ingredient the compound or its salt which n represents the integer of 1-5.
[10" claim-type="Currently amended] The compound of claim 9, wherein A represents — (NR ⁴ ) — or — (CR ⁵ R ⁶ ) —;
B represents an alkylene group or an alkenylene group;
R ¹ represents an alkyl group or an alkenyl group, and the alkyl group may be substituted with a halogen atom, an amino group, a cycloalkyl group, an aryl group, an imidazole group or a pyridine ring, and the amino group may be an alkyl group, an acyl group, an alkoxycarbonyl group or a cycloalkyl group. It may be substituted by the oxycarbonyl group or the arylalkoxycarbonyl group;
R ² represents an alkyl group, an alkenyl group or an arylalkyl group;
R ³ represents a pyridine ring;
R ⁴ represents a hydrogen atom;
R ⁵ and R ⁶ represent a hydrogen atom;
An angiogenesis inhibitor, wherein X comprises = O or a salt thereof as an active ingredient.
[11" claim-type="Currently amended] The angiogenesis inhibitor according to claim 10, wherein R ¹ comprises an alkyl group, and R ² comprises an alkyl group or an arylalkyl group or a salt thereof as an active ingredient.
[12" claim-type="Currently amended] The compound of claim 9, wherein A represents — (NR ⁴ ) — or — (CR ⁵ R ⁶ ) —;
B represents an alkylene group or an alkenylene group;
R ¹ represents an alkyl group, an alkenyl group or a cycloalkyl group, and the alkyl group is substituted with a halogen atom, a hydroxy group, an amino group, a cycloalkyl group, an aryl group, a carboxyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, a pyridine ring or a thiophene ring The hydrogen atom of each of the amino, hydroxy and aminocarbonyl groups described above may be substituted with an alkyl group, an aryl group, an arylalkyl group, an acyl group, an alkoxycarbonyl group, a cycloalkyloxycarbonyl group or an arylalkoxycarbonyl group;
R ² represents a cycloalkyl group or a cycloalkylalkyl group;
R ³ represents a pyridine ring;
R ⁴ represents a hydrogen atom;
R ⁵ and R ⁶ represent a hydrogen atom;
An angiogenesis inhibitor, wherein X comprises = O or a salt thereof as an active ingredient.
[13" claim-type="Currently amended] A therapeutic agent for ophthalmic diseases involving angiogenesis comprising the compound according to any one of claims 1 to 12 or a salt thereof as an active ingredient.
[14" claim-type="Currently amended] The therapeutic agent according to claim 13, wherein the ophthalmic disease is diabetic retinopathy, prematurity retinopathy, macular degeneration, angiographic glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, or corneal neovascularization.
[15" claim-type="Currently amended] A therapeutic agent for cancer diseases involving angiogenesis, comprising the compound according to any one of claims 1 to 12 or a salt thereof as an active ingredient.
[16" claim-type="Currently amended] The therapeutic agent according to claim 15, wherein the cancer disease is a solid tumor, angioma, or tumor proliferation or metastasis.
[17" claim-type="Currently amended] A method for treating an ocular disease involving angiogenesis, comprising administering to a patient an effective amount of a compound according to any one of claims 1 to 12 or a salt thereof.
[18" claim-type="Currently amended] 18. The method of claim 17, wherein the ocular disease is diabetic retinopathy, prematurity retinopathy, macular degeneration, angiographic glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis or corneal neovascularization.
[19" claim-type="Currently amended] A method for the treatment of cancer diseases involving angiogenesis, comprising administering to a patient an effective amount of a compound according to any one of claims 1 to 12 or a salt thereof.
[20" claim-type="Currently amended] The method of claim 19, wherein the cancer disease is a solid tumor, angioma, or tumor proliferation or metastasis.
[21" claim-type="Currently amended] Use of a compound of any one of claims 1 to 12 or salts thereof for the manufacture of a therapeutic agent for an ocular disease with angiogenesis.
[22" claim-type="Currently amended] Use according to claim 21, wherein the ophthalmic disease is diabetic retinopathy, prematurity retinopathy, macular degeneration, angiographic glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis or corneal neovascularization.
[23" claim-type="Currently amended] Use of a compound of any one of claims 1 to 12 or salts thereof for the manufacture of a therapeutic agent for cancer diseases involving angiogenesis.
[24" claim-type="Currently amended] Use according to claim 23, wherein the cancer disease is a solid tumor, angioma, or a tumor's proliferation or metastasis.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US9975891B2|2018-05-22|Lactam-containing compounds and derivatives thereof as factor Xa inhibitors

---

AU2014222756B2|2018-07-26|Inhibitors of histone demethylases

---

US20150353538A1|2015-12-10|Compounds and therapeutic uses thereof

---

US9242963B2|2016-01-26|Organic compounds

---

US8536165B2|2013-09-17|Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors

---

JP4533466B2|2010-09-01|Inhibitors of protein isoprenyl transferase

---

AP1388A|2005-04-14|Nicotinamide derivatives

---

CA2277273C|2008-03-25|Integrin antagonists

---

KR100567266B1|2006-04-03|Piperidine compounds as anti-allergic

---

US8049015B2|2011-11-01|Heteroaryl antagonists of prostaglandin D2 receptors

---

AU724191B2|2000-09-14|Integrin antagonists

---

US5294616A|1994-03-15|Fibrinogen receptor antagonists

---

EP1140905B1|2003-05-14|Heteroaromatic amides as inhibitor of factor xa

---

CA2426601C|2015-01-13|Cyanoguanidine prodrugs

---

JP3856465B2|2006-12-13|Trisubstituted phenyl derivatives useful as PDE IV inhibitors

---

AU721130B2|2000-06-22|Fibrinogen receptor antagonists

---

JP5107058B2|2012-12-26|3-heterocyclic-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and / or immunostimulatory activity

---

US7115627B2|2006-10-03|Glycinamides as factor Xa inhibitors

---

RU2626956C2|2017-08-02|1-phenyl-2-pyridinylalkyl alcohols derivatives as phosphodiesterase inhibitors

---

AP781A|1999-11-04|Amino acid derivatives with multi-drug resistance activity, compositions and uses thereof and processes for preparing said derivatives.

---

US8026239B2|2011-09-27|Cell differentiation inducer

---

US7005435B2|2006-02-28|Lactam-containing compounds and derivatives thereof as factor Xa inhibitors

---

US8188277B2|2012-05-29|Aromatic compounds for suppressing the generation of collagen

---

EP1536797B1|2007-04-04|1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related comounds as neurokinin-1 | antagonsists for the treatment of emesis, depression, anxiety and cough

---

AU2002243692B2|2006-06-08|Substituted indoles and their use as integrin antagonists

同族专利:

---

公开号 | 公开日

---

US20080161270A1|2008-07-03|

---

CN1604774A|2005-04-06|

---

EP1457205A4|2006-07-05|

---

AU2002349621A1|2003-06-10|

---

EP1457205A1|2004-09-15|

---

US7741346B2|2010-06-22|

---

CA2468704A1|2003-06-05|

---

KR100944174B1|2010-02-24|

---

CA2468704C|2011-06-14|

---

US20050014800A1|2005-01-20|

---

WO2003045367A1|2003-06-05|

---

CN100522150C|2009-08-05|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2001-11-30|Priority to JP2001366088

---

2001-11-30|Priority to JPJP-P-2001-00366088

---

2002-11-29|Application filed by 산텐 세이야꾸 가부시키가이샤

---

2002-11-29|Priority to PCT/JP2002/012481

---

2004-07-03|Publication of KR20040058349A

---

2010-02-24|Application granted

---

2010-02-24|Publication of KR100944174B1

优先权:

---

申请号 | 申请日 | 专利标题

---

JP2001366088|2001-11-30|

---

JPJP-P-2001-00366088|2001-11-30|

---

PCT/JP2002/012481|WO2003045367A1|2001-11-30|2002-11-29|Angiogenesis inhibitor|